Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

Open in Screener

COSM

Cosmos Health Inc

Jan 21 • 04:00PM ET

0.5200

+0.0247 4.99 %

Healthcare • Medical Distribution • Greece • NASD

Peers: VRTX OPK CERS MBAI AUPH VNDA HOOK XOMA NNVC

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-0.71	Insider Own	33.33%	Shs Outstand	31.87M	Perf Week	11.21%
Market Cap	19.46M	Forward P/E	-	EPS next Y	-0.34	Insider Trans	18.33%	Shs Float	24.96M	Perf Month	2.56%
Enterprise Value	38.99M	PEG	-	EPS next Q	-0.04	Inst Own	3.25%	Short Float	0.58%	Perf Quarter	-50.00%
Income	-18.54M	P/S	0.33	EPS this Y	-	Inst Trans	2.87%	Short Ratio	0.19	Perf Half Y	8.58%
Sales	59.79M	P/B	0.72	EPS next Y	-	ROA	-27.67%	Short Interest	0.15M	Perf YTD	4.42%
Book/sh	0.73	P/C	4.17	EPS next 5Y	62.88%	ROE	-63.82%	52W High	1.32 -60.61%	Perf Year	-39.35%
Cash/sh	0.12	P/FCF	-	EPS past 3/5Y	63.35% 28.41%	ROIC	-63.34%	52W Low	0.28 85.65%	Perf 3Y	-86.46%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-1.09% 6.53%	Gross Margin	9.12%	Volatility	19.22% 10.83%	Perf 5Y	-99.61%
Dividend TTM	-	EV/Sales	0.65	EPS Y/Y TTM	58.81%	Oper. Margin	-22.48%	ATR (14)	0.06	Perf 10Y	-99.78%
Dividend Ex-Date	-	Quick Ratio	0.84	Sales Y/Y TTM	-	Profit Margin	-31.01%	RSI (14)	49.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.99	EPS Q/Q	61.57%	SMA20	1.42%	Beta	4.46	Target Price	4.50
Payout	-	Debt/Eq	1.05	Sales Q/Q	37.86%	SMA50	-6.28%	Rel Volume	2.78	Prev Close	0.50
Employees	149	LT Debt/Eq	0.27	Earnings	Nov 17 BMO	SMA200	-18.82%	Avg Volume	760.32K	Price	0.52
IPO	Jul 23, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	- -	Trades		Volume	2,066,646	Change	4.99%

Jan-20-26 10:45AM	Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue (GlobeNewswire) -5.57%
Jan-14-26 11:25AM	Cosmos Health Announces Initiation of Analyst Coverage with $4.50 Valuation by Zacks Small-Cap Research (GlobeNewswire)
Jan-05-26 09:30AM	Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle Medicine, with Five-Year Volumes Expected to Exceed 1.2 Million Units (GlobeNewswire)
Dec-24-25 09:00AM	Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy (ACCESSWIRE)
Dec-19-25 09:00AM	Cosmos Health is Forcing the Market to Reframe the Conversation (ACCESSWIRE)
12:20PM	Loading…
Dec-03-25 12:20PM	Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets (GlobeNewswire) -10.81%
Dec-02-25 12:15PM	Cosmos Health CEO Greg Siokas Adds 3,398,055 Shares Year-to-Date 2025 Following Continued November Purchases (GlobeNewswire)
Nov-17-25 09:15AM	Cosmos Health Reports Record Q3 2025 Results with All-Time High Revenue, Gross Profit and Gross Margin; Revenue Up 38% to $17.1M, Gross Profit Up 116% to $2.6M, Adjusted EBITDA Up 74%, Cash Position Up to $4.63M from $0.66M (GlobeNewswire)
Oct-31-25 10:45AM	Cosmos Health Enters New Nanotechnology R&D Program to Develop Next-Generation Nutraceutical Formulas with Enhanced Phytochemical Efficacy (GlobeNewswire) -10.01%
Oct-21-25 12:10PM	Cosmos Health Expands Its Ethereum Holdings With an Additional $200,000 Purchase Under Its $300 Million Digital Assets Facility; Total Investment Now Reaches $2 Million (GlobeNewswire)
Oct-16-25 08:00AM	Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -12.80%
Oct-13-25 02:05PM	Cosmos Health Purchases an Additional $300,000 in Ethereum Under Its $300 Million Digital Assets Facility; Total Investment Reaches $1.8 Million (GlobeNewswire)
Oct-10-25 08:00AM	Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility (GlobeNewswire)
Oct-03-25 03:56PM	Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units (GlobeNewswire)
Sep-29-25 08:00AM	Cosmos Health CEO Issues Letter to Shareholders: Building a Global Healthcare Powerhouse with $300M Digital Financing Facility, U.S. Manufacturing Expansion, and AI Innovation (GlobeNewswire)
08:00AM	Loading…
Sep-25-25 08:00AM	Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL Pessaries Annually (GlobeNewswire)
Sep-22-25 08:00AM	Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue (GlobeNewswire) +15.39%
Sep-11-25 08:00AM	Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units (GlobeNewswire) +10.51%
Aug-18-25 12:45PM	Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025 (GlobeNewswire) -5.27%
Aug-12-25 09:50AM	Cosmos Health Makes Initial $1M Ethereum Purchase Under Digital Asset Treasury Strategy (GlobeNewswire)
Aug-07-25 09:25AM	Cosmos Health secures $300M financing facility to launch Ethereum strategy (TipRanks) -8.70%
Aug-06-25 09:20AM	Cosmos Health Secures up to $300 Million Financing Facility to Launch Ethereum Treasury Strategy (GlobeNewswire) +30.98%
Jun-25-25 11:00AM	Cosmos Health enters U.S. market with DolCas Biotech agreement (TipRanks)
Jun-24-25 10:55AM	Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech (GlobeNewswire)
May-15-25 02:30PM	RETRANSMISSION - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven (GlobeNewswire)
09:30AM	Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven (GlobeNewswire)
May-07-25 02:30PM	Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units (GlobeNewswire)
May-06-25 01:40PM	Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq (GlobeNewswire)
Apr-30-25 12:50PM	Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 (GlobeNewswire)
Apr-16-25 12:45PM	Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million (GlobeNewswire)
01:40PM	Loading…
Apr-09-25 01:40PM	Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L (GlobeNewswire)
Apr-08-25 10:45AM	Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order (GlobeNewswire)
Feb-26-25 11:30AM	Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates (ACCESSWIRE)
Feb-18-25 08:30AM	Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 (ACCESSWIRE)
Feb-11-25 10:15AM	Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market (ACCESSWIRE) -10.28%
Feb-10-25 01:30PM	Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market (ACCESSWIRE)
09:45AM	Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations (ACCESSWIRE)
Feb-07-25 10:00AM	Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility (ACCESSWIRE)
Feb-06-25 03:50PM	Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar (ACCESSWIRE)
Feb-05-25 11:05AM	Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market (ACCESSWIRE)
Jan-28-25 11:00AM	Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow (ACCESSWIRE) -11.39%
Jan-27-25 03:50PM	Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion (ACCESSWIRE)
Jan-23-25 03:35PM	Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait (ACCESSWIRE)
Jan-22-25 08:00AM	Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million (ACCESSWIRE) -17.08%
Jan-21-25 03:00PM	Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days (ACCESSWIRE) +8.47%
Jan-14-25 09:41AM	Cosmos Health secures exclusive distribution agreement with Virax Biolabs (TipRanks) +12.55%
Jan-13-25 09:20AM	Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries (ACCESSWIRE)
Dec-26-24 01:30PM	Cosmos Health Strengthens RandD Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology (ACCESSWIRE)
01:30PM	Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology (ACCESSWIRE)
Dec-23-24 09:25AM	Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000 (ACCESSWIRE) +6.02%
Nov-26-24 09:30AM	Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price (ACCESSWIRE)
Nov-18-24 08:00AM	Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets (ACCESSWIRE) +11.13%
Nov-15-24 10:20AM	Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M (ACCESSWIRE)
Nov-12-24 12:00PM	Cosmos Health Issues Letter to Shareholders (ACCESSWIRE) +7.09%
Nov-01-24 12:30PM	Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% (ACCESSWIRE) -5.32%
Sep-25-24 09:25AM	Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands (ACCESSWIRE) -10.27%
Sep-23-24 12:55PM	Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins (ACCESSWIRE) -8.18%
09:00AM	Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits (ACCESSWIRE)
Sep-19-24 03:40PM	Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion (ACCESSWIRE)
Sep-18-24 01:30PM	Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments (ACCESSWIRE)
Sep-17-24 11:45AM	Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price (ACCESSWIRE) +13.43%
Sep-16-24 08:30AM	Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc. (PR Newswire)
08:30AM	Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar (ACCESSWIRE)
Aug-23-24 09:35AM	Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements (ACCESSWIRE)
Aug-21-24 10:20AM	Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits (ACCESSWIRE) +17.76%
Aug-20-24 12:20PM	Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023 (ACCESSWIRE) -15.08%
09:00AM	Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit (ACCESSWIRE)
Aug-08-24 01:00PM	Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market (ACCESSWIRE)
Aug-06-24 09:00AM	Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share (ACCESSWIRE) +15.00%
Jul-25-24 02:45PM	Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland (ACCESSWIRE) +5.79%
11:40AM	Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar (ACCESSWIRE)
Jul-24-24 10:55AM	Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity (ACCESSWIRE)
Jul-19-24 11:40AM	Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule (ACCESSWIRE)
Jul-18-24 03:45PM	Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units (ACCESSWIRE) -10.36%
Jul-10-24 03:45PM	Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market (ACCESSWIRE)
Jul-09-24 02:00PM	Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually (ACCESSWIRE)
Jul-03-24 01:05PM	Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE (ACCESSWIRE) -10.89%
Jul-02-24 03:30PM	Cosmos Health Expands Collaboration with Papaellinas in Cyprus; Sky Premium Life Sales Expected to More Than Double to 150,000 Units Over Next 12 Months (ACCESSWIRE) -8.18%
Jul-01-24 11:20AM	Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leading Pharmacy and Retail Chains (ACCESSWIRE) +5.77%
Jun-28-24 08:12AM	Why Is Cosmos Health (COSM) Stock Up 65% Today? (InvestorPlace) +53.17%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 03:45PM	Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units (ACCESSWIRE) +5.27%
Jun-18-24 10:00AM	Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent (ACCESSWIRE)
Jun-13-24 09:25AM	Cosmos Health Completes Acquisition of Pelofarm's Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million (ACCESSWIRE)
May-24-24 04:30PM	Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q (ACCESSWIRE) +5.87%
May-17-24 10:15AM	Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand (ACCESSWIRE)
Apr-30-24 09:42AM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Healthcare Stocks (InvestorPlace)
Apr-19-24 04:30PM	Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K (ACCESSWIRE) -20.39%
Mar-21-24 09:45AM	Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform (ACCESSWIRE) -7.78%
Mar-19-24 10:10AM	Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market (ACCESSWIRE)
Mar-18-24 09:25AM	Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders (ACCESSWIRE) -5.34%
Feb-29-24 09:25AM	Cosmos Health Successfully Completes Acquisition of Pharmatrade's Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million (ACCESSWIRE)
Feb-23-24 12:00AM	As Trading Frenzies Grip Penny Stocks, Criticism of Nasdaq Grows (The Wall Street Journal)
Feb-21-24 11:50AM	Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price (ACCESSWIRE)
09:30AM	Taglich Brothers Initiates Coverage of Cosmos Health Inc. (GlobeNewswire)
Feb-20-24 09:25AM	Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company (ACCESSWIRE)
Feb-01-24 09:25AM	Taglich Brothers Initiates Coverage of Cosmos Health Inc. (ACCESSWIRE)
Jan-23-24 01:05PM	Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market (ACCESSWIRE)
Jan-18-24 09:25AM	Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio (ACCESSWIRE)
Dec-27-23 09:27AM	Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023 (ACCESSWIRE) +10.07%

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Siokas Grigorios	Chief Executive Officer	Jan 20 '26	Buy	0.50	353,321	175,000	8,091,795	Jan 21 10:11 AM
Siokas Grigorios	Chief Executive Officer	Jan 14 '26	Buy	0.45	493,495	220,000	7,738,474	Jan 15 09:40 AM
Siokas Grigorios	Chief Executive Officer	Jan 12 '26	Buy	0.50	113,185	57,000	7,244,979	Jan 13 10:00 AM
Siokas Grigorios	Chief Executive Officer	Jan 08 '26	Buy	0.52	156,190	81,000	7,131,794	Jan 09 11:43 AM
Siokas Grigorios	Chief Executive Officer	Jan 07 '26	Buy	0.52	124,880	65,000	6,975,604	Jan 08 10:41 AM
Siokas Grigorios	Chief Executive Officer	Jan 06 '26	Buy	0.54	133,953	72,000	6,850,724	Jan 07 01:01 PM
Siokas Grigorios	Chief Executive Officer	Dec 19 '25	Buy	0.49	88,314	43,000	6,716,771	Dec 22 10:45 AM
Siokas Grigorios	Chief Executive Officer	Dec 15 '25	Buy	0.42	168,472	70,000	6,628,457	Dec 16 12:17 PM
Siokas Grigorios	Chief Executive Officer	Nov 28 '25	Buy	0.64	76,360	49,000	6,459,985	Dec 01 12:02 PM
Siokas Grigorios	Chief Executive Officer	Nov 25 '25	Buy	0.63	55,732	35,000	6,383,625	Nov 26 12:52 PM
Siokas Grigorios	Chief Executive Officer	Nov 21 '25	Buy	0.68	56,080	38,000	6,327,893	Nov 24 02:47 PM
Siokas Grigorios	Chief Executive Officer	Nov 20 '25	Buy	0.62	51,315	32,000	6,271,813	Nov 21 10:07 AM
Siokas Grigorios	Chief Executive Officer	Nov 19 '25	Buy	0.65	61,614	40,000	6,220,498	Nov 20 11:06 AM
Siokas Grigorios	Chief Executive Officer	May 23 '25	Buy	0.45	34,004	15,217	6,158,884	May 27 09:33 AM
Siokas Grigorios	Chief Executive Officer	May 22 '25	Buy	0.44	141,825	62,800	6,124,880	May 23 12:18 PM
Siokas Grigorios	Chief Executive Officer	May 21 '25	Buy	0.47	174,172	82,000	5,983,055	May 22 10:33 AM
Siokas Grigorios	Chief Executive Officer	May 20 '25	Buy	0.45	147,563	65,961	5,808,883	May 21 10:20 AM
Siokas Grigorios	Chief Executive Officer	May 19 '25	Buy	0.43	79,254	34,000	5,661,320	May 20 09:51 AM
Siokas Grigorios	Chief Executive Officer	Apr 24 '25	Buy	0.40	254,618	102,000	5,582,066	Apr 28 10:49 AM
Siokas Grigorios	Chief Executive Officer	Apr 24 '25	Buy	0.40	177,234	71,000	5,327,448	Apr 25 10:07 AM
Siokas Grigorios	Chief Executive Officer	Apr 23 '25	Buy	0.40	205,000	82,000	5,150,214	Apr 24 09:48 AM
Siokas Grigorios	Chief Executive Officer	Apr 22 '25	Buy	0.36	175,000	63,000	4,945,214	Apr 23 10:43 AM
Siokas Grigorios	Chief Executive Officer	Apr 21 '25	Buy	0.32	654,912	208,000	4,770,214	Apr 22 09:59 AM
Siokas Grigorios	Chief Executive Officer	Mar 04 '25	Buy	0.53	85,714	45,000	4,115,302	Mar 05 11:05 AM
Siokas Grigorios	Chief Executive Officer	Mar 03 '25	Buy	0.49	132,572	65,000	4,029,588	Mar 04 12:32 PM
Siokas Grigorios	Chief Executive Officer	Feb 24 '25	Buy	0.56	354,296	200,000	3,897,016	Feb 25 09:49 AM
Siokas Grigorios	Chief Executive Officer	Jan 30 '25	Buy	0.66	51,414	34,000	4,255,103	Jan 31 09:46 AM

Open in Screener

CABA

Cabaletta Bio Inc

Jan 21 • 04:00PM ET

2.34

+0.15 6.85 %

Healthcare • Biotechnology • USA • NASD

CABA Cabaletta Bio Inc daily Stock Chart

Peers: CRSP BLUE BMRN EDIT TGTX NTLA ALLO SGMO ANIX ADAP

| Held by: VTI VXF IBB IWC PRFZ DFAS AVSC TMED BTEC IBBQ

Index	-	P/E	-	EPS (ttm)	-2.53	Insider Own	12.29%	Shs Outstand	96.27M	Perf Week	8.84%
Market Cap	225.26M	Forward P/E	-	EPS next Y	-1.77	Insider Trans	1.13%	Shs Float	84.43M	Perf Month	-2.90%
Enterprise Value	91.11M	PEG	-	EPS next Q	-0.46	Inst Own	64.36%	Short Float	22.26%	Perf Quarter	-17.02%
Income	-158.52M	P/S	-	EPS this Y	7.33%	Inst Trans	-1.23%	Short Ratio	6.14	Perf Half Y	48.10%
Sales	0.00M	P/B	1.62	EPS next Y	18.28%	ROA	-80.43%	Short Interest	18.80M	Perf YTD	6.85%
Book/sh	1.45	P/C	1.41	EPS next 5Y	9.29%	ROE	-101.06%	52W High	3.67 -36.24%	Perf Year	-14.60%
Cash/sh	1.66	P/FCF	-	EPS past 3/5Y	-9.16% -20.35%	ROIC	-110.07%	52W Low	0.99 137.39%	Perf 3Y	-76.65%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.53% 6.30%	Perf 5Y	-82.98%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-17.21%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.32	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	3.60	EPS Q/Q	29.14%	SMA20	6.97%	Beta	3.26	Target Price	13.57
Payout	-	Debt/Eq	0.18	Sales Q/Q	-	SMA50	1.43%	Rel Volume	0.68	Prev Close	2.19
Employees	161	LT Debt/Eq	0.03	Earnings	Nov 10 BMO	SMA200	20.11%	Avg Volume	3.06M	Price	2.34
IPO	Oct 25, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.72% -	Trades		Volume	2,320,652	Change	6.85%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-10-25	Resumed	Jefferies	Buy	$14
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line	$15 → $6
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$12 → $6
Oct-10-24	Initiated	UBS	Buy	$10
Feb-05-24	Initiated	Jefferies	Buy	$36
Nov-29-23	Initiated	William Blair	Outperform	$38
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$40
Oct-19-23	Initiated	Stifel	Buy	$31
Sep-05-23	Initiated	Citigroup	Buy	$22
Jul-18-23	Initiated	Guggenheim	Buy	$34
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$3 → $16
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$15 → $3
Dec-08-21	Initiated	Wells Fargo	Overweight	$17
Oct-19-21	Resumed	Morgan Stanley	Overweight	$20
Jun-30-21	Initiated	Mizuho	Buy	$22
Jan-08-21	Initiated	Chardan Capital Markets	Buy	$21
Oct-13-20	Initiated	H.C. Wainwright	Buy	$20
Nov-19-19	Initiated	Morgan Stanley	Overweight	$19
Nov-19-19	Initiated	Evercore ISI	Outperform	$25
Nov-19-19	Initiated	Cowen	Outperform

Show Previous Ratings

Jan-12-26 08:00AM	Cabaletta Bio Announces 2026 Strategic Priorities (GlobeNewswire) +5.24%
07:30AM	IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms (Business Wire)
Nov-10-25 07:30AM	Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 09:40AM	Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year? (Zacks) -10.30%
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December (GlobeNewswire)
05:42AM	Loading…
Oct-31-25 05:42AM	Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials (Insider Monkey) +46.15%
Oct-27-25 07:00AM	Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 (GlobeNewswire) +12.96%
Oct-14-25 08:00AM	Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant (GlobeNewswire) +16.06%
Oct-09-25 12:00PM	Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress (GlobeNewswire) +18.26%
Aug-27-25 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-11-25 12:00PM	Cabaletta Bio (CABA) Upgraded to Buy: Here's Why (Zacks)
Aug-07-25 07:30AM	Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jun-11-25 09:54AM	Cabaletta Bio Announces Pricing of Public Offering of Securities (GlobeNewswire) -25.53%
06:15AM	Cabaletta Bio Announces Proposed Public Offering of Securities (GlobeNewswire)
06:00AM	Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress (GlobeNewswire)
08:00AM	Loading…
May-29-25 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-25 10:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-15-25 07:00AM	Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts (GlobeNewswire) +39.23%
Apr-01-25 12:16PM	Rocket acquires Mr. Cooper, Musks xAI acquires X: Morning Buzz (TipRanks) -15.52%
Mar-31-25 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.65%
Mar-19-25 07:00AM	Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle Platform (Business Wire) +6.59%
Feb-26-25 08:00AM	Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-18-25 10:21AM	UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire) -14.02%
07:00AM	Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings (GlobeNewswire)
Feb-11-25 08:00AM	Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February (GlobeNewswire)
Jan-29-25 08:00AM	Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025 (GlobeNewswire)
Nov-26-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in December (GlobeNewswire) +5.68%
Nov-18-24 07:00AM	Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 (GlobeNewswire) -10.89%
Nov-14-24 07:00AM	Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.74%
08:00AM	Loading…
Nov-06-24 08:00AM	Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire) +10.71%
Oct-17-24 03:06PM	State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings (GuruFocus.com)
Sep-25-24 04:30PM	Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Aug-21-24 04:32AM	Several Headwinds Dragged Cabaletta Bio (CABA) in Q2 (Insider Monkey) +20.65%
Aug-08-24 07:00AM	Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -34.37%
Jul-08-24 07:01PM	Cabaletta Bio, Inc. (CABA): Why Are Analysts Loving This Shorted Stock Right Now? (Insider Monkey) +7.23%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-02-24 08:00AM	Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum (GlobeNewswire) -5.38%
Jun-14-24 02:00AM	Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis and RESET-SLE Trials of CABA-201 (GlobeNewswire) -15.13%
May-29-24 08:00AM	Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -5.81%
May-16-24 05:23PM	Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake (Investopedia)
May-15-24 11:54AM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 (InvestorPlace) +13.00%
07:00AM	Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Mar-23-24 05:31AM	Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway (GuruFocus.com)
Mar-21-24 01:53PM	CABA Stock Earnings: Cabaletta Bio Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-20-24 07:00AM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis (GlobeNewswire)
Mar-08-24 08:50AM	Jim Cramer's 10 Latest Stock Picks This Week (Insider Monkey)
Feb-27-24 10:11AM	Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4 (Insider Monkey)
08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
Feb-01-24 04:30PM	Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis (GlobeNewswire) +7.05%
Jan-31-24 08:00AM	Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-08-24 07:00AM	Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis (GlobeNewswire) +8.70%
Jan-02-24 08:00AM	Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 08:49PM	Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally (TipRanks) +7.14%
Nov-28-23 04:30PM	Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire) -26.79%
Nov-09-23 08:10AM	Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress (GuruFocus.com)
07:00AM	Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:15AM	Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabalettas CD19-CAR T Cell Therapy on Cellares Cell Shuttle Platform (Business Wire)
07:00AM	Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis (GlobeNewswire)
Oct-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November (GlobeNewswire) +7.50%
Oct-09-23 09:40AM	Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year? (Zacks) +5.70%
Oct-02-23 09:14AM	QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software (Zacks)
07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 (GlobeNewswire)
Oct-01-23 11:00AM	Top Stocks for October 2023 (Investopedia)
Sep-25-23 08:50AM	What Makes Cabaletta Bio, Inc. (CABA) a Good Fit for 'Trend Investing' (Zacks)
Sep-19-23 08:00AM	Cabaletta Bio to Participate in Upcoming Investor Conferences in September (GlobeNewswire) -6.92%
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -5.93%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:55AM	Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade (Zacks)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-30-23 08:00AM	Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-23 10:13AM	Lab Notes: Wistar, Coriell researchers identify potential target for gastric cancers treatment (American City Business Journals)
Aug-23-23 08:50AM	Recent Price Trend in Cabaletta Bio, Inc. (CABA) is Your Friend, Here's Why (Zacks)
Aug-22-23 08:00AM	Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 (GlobeNewswire)
Aug-15-23 01:46PM	Does Cabaletta Bio, Inc. (CABA) Have the Potential to Rally 27.85% as Wall Street Analysts Expect? (Zacks)
Aug-10-23 07:00AM	Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-01-23 10:00AM	Top Stocks for August 2023 (Investopedia) -7.27%
Jul-24-23 08:00AM	Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors (GlobeNewswire) -6.68%
Jul-18-23 02:58PM	Why Shares of Cabaletta Bio Are Up Tuesday (Motley Fool) +11.93%
Jun-20-23 08:00AM	Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors (GlobeNewswire) -5.26%
Jun-08-23 11:14AM	Top Healthcare Stocks for June 2023 (Investopedia)
May-31-23 08:00AM	Cabaletta Bio to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-24-23 07:33AM	Institutional investors in Cabaletta Bio, Inc. (NASDAQ:CABA) lost 18% last week but have reaped the benefits of longer-term growth (Simply Wall St.)
May-22-23 04:30PM	Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares (GlobeNewswire)
May-17-23 10:16PM	Cabaletta Bio Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.83%
04:01PM	Cabaletta Bio Announces Proposed Public Offering of Common Stock (GlobeNewswire)
May-16-23 07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis (GlobeNewswire) +14.63%
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia) +6.67%
07:00AM	Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-02-23 04:35PM	Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +5.70%
May-01-23 07:00AM	Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 (GlobeNewswire) +9.83%
Apr-25-23 01:07PM	Great news for Cabaletta Bio, Inc. (NASDAQ:CABA): Insiders acquired stock in large numbers last year (Simply Wall St.) -5.94%
08:00AM	Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-13-23 04:30PM	Cabaletta Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-23 07:00AM	Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Systemic Lupus Erythematosus (GlobeNewswire) +16.48%
Mar-16-23 07:00AM	Cabaletta Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-14-23 07:14AM	We're Keeping An Eye On Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate (Simply Wall St.) +8.02%

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chang David J.	Chief Medical Officer	Jan 21 '26	Buy	2.26	8,800	19,888	8,800	Jan 21 06:56 PM
Binder Gwendolyn	President, Science & Tech.	Jan 21 '26	Buy	2.19	11,312	24,763	31,312	Jan 21 06:56 PM
Tomasello Shawn	Director	Jan 21 '26	Buy	2.21	22,725	50,322	22,725	Jan 21 06:55 PM
Gavel Steve	Chief Commercial Officer	Jan 21 '26	Buy	2.27	22,170	50,215	22,170	Jan 21 06:55 PM
Bollard Catherine	Director	Jan 21 '26	Buy	2.27	4,405	9,982	5,405	Jan 21 06:54 PM
Nichtberger Steven	President & CEO	Jan 21 '26	Buy	2.24	45,000	100,778	1,031,483	Jan 21 06:54 PM
Simon Mark	Director	Jan 21 '26	Buy	2.28	11,061	25,261	147,205	Jan 21 06:53 PM
Gerard Michael	General Counsel	Jan 21 '26	Buy	2.27	6,600	14,979	6,600	Jan 21 06:53 PM

Open in Screener

ACRV

Acrivon Therapeutics Inc

Jan 21 • 04:00PM ET

2.09

+0.13 6.63 %

Healthcare • Biotechnology • USA • NASD

ACRV Acrivon Therapeutics Inc daily Stock Chart

Peers: BMRN VRTX REGN AMGN GILD BIIB EXEL INCY NBIX IONS

| Held by: VTI VXF IWC CHNA

Index	-	P/E	-	EPS (ttm)	-2.13	Insider Own	29.46%	Shs Outstand	31.55M	Perf Week	22.94%
Market Cap	65.95M	Forward P/E	-	EPS next Y	-1.96	Insider Trans	0.74%	Shs Float	22.26M	Perf Month	-7.52%
Enterprise Value	-60.31M	PEG	-	EPS next Q	-0.48	Inst Own	48.08%	Short Float	23.92%	Perf Quarter	8.85%
Income	-81.75M	P/S	-	EPS this Y	14.91%	Inst Trans	-0.64%	Short Ratio	3.13	Perf Half Y	50.36%
Sales	0.00M	P/B	0.51	EPS next Y	3.37%	ROA	-45.42%	Short Interest	5.33M	Perf YTD	-13.28%
Book/sh	4.08	P/C	0.51	EPS next 5Y	6.86%	ROE	-50.23%	52W High	8.00 -73.88%	Perf Year	-63.84%
Cash/sh	4.10	P/FCF	-	EPS past 3/5Y	-45.20% -74.96%	ROIC	-62.69%	52W Low	1.05 99.05%	Perf 3Y	-83.17%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	9.75% 12.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	21.17%	Oper. Margin	-	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.75	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.99	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	8.75	EPS Q/Q	19.70%	SMA20	-5.28%	Beta	1.77	Target Price	11.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-8.33%	Rel Volume	0.56	Prev Close	1.96
Employees	78	LT Debt/Eq	0.01	Earnings	Nov 13 AMC	SMA200	24.20%	Avg Volume	1.70M	Price	2.09
IPO	Nov 15, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	20.49% -	Trades		Volume	957,763	Change	6.63%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-25	Resumed	Piper Sandler	Overweight	$6
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy	$16
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform	$14
Dec-15-23	Resumed	Jefferies	Buy	$17 → $12
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform	$25
May-08-23	Initiated	BMO Capital Markets	Outperform	$25
Apr-27-23	Initiated	Ladenburg Thalmann	Buy	$22
Apr-20-23	Initiated	H.C. Wainwright	Buy	$24
Dec-12-22	Initiated	Piper Sandler	Overweight	$25
Dec-12-22	Initiated	Jefferies	Buy	$17
Dec-12-22	Initiated	Cowen	Outperform

Show Previous Ratings

Jan-08-26 02:02PM	Small-Cap Acrivon Highlights Tumor Shrinkage And Trial Progress Across Key Studies, Stock Falls (Benzinga) -34.58%
07:30AM	Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 (GlobeNewswire)
Jan-07-26 09:40AM	Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-06-26 07:30AM	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast (GlobeNewswire) +31.44%
Dec-17-25 09:34AM	UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast (GlobeNewswire)
07:30AM	Loading…
07:30AM	Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates (GlobeNewswire)
Nov-29-25 01:26AM	H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With "Buy" Rating and $19 PT (Insider Monkey)
Nov-13-25 04:10PM	Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) -9.21% +8.21%
Nov-02-25 05:05AM	Analysts Predict Up to 550% Rally for These 2 Strong Buy Penny Stocks (TipRanks)
Oct-22-25 04:15PM	Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-01-25 04:30PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-13-25 04:15PM	Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) +6.11%
May-17-25 12:30PM	Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch (TipRanks)
May-14-25 04:10PM	Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-05-25 09:55AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) Is a Great 'Buy the Bottom' Stock Now (Zacks)
12:23PM	Loading…
Apr-28-25 12:23PM	Can Humana Beat Q1 Earnings Estimates on Growing Premiums? (Zacks) -5.49%
Apr-25-25 08:00AM	Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025 (GlobeNewswire) -17.59%
Apr-24-25 11:00AM	Universal Health to Report Q1 Earnings: Can it Surprise Wall Street? (Zacks)
Apr-23-25 01:41PM	HCA Healthcare to Report Q1 Earnings: Key Estimates to Note (Zacks)
01:28PM	Can Centene Beat Q1 Earnings Estimates on Growing Premiums? (Zacks)
Apr-22-25 11:19AM	Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch (Zacks) +6.28%
Apr-14-25 09:35AM	Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) (Zacks) -7.41%
Apr-07-25 04:05PM	Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer (GlobeNewswire) -7.95%
Mar-28-25 12:00PM	Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know (Zacks) -11.11%
09:35AM	Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks (Zacks)
Mar-27-25 05:44PM	Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-19-25 08:00AM	Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates (GlobeNewswire)
Feb-06-25 08:16AM	Acrivon Therapeutics announces FDA granted BDD for ACR-368 (TipRanks) -6.60%
04:54AM	FDA grants breakthrough designation for Acrivons endometrial cancer assay (Medical Device Network)
Feb-05-25 03:45PM	Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status (Insider Monkey) +17.94%
08:00AM	Loading…
08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer (GlobeNewswire)
Nov-13-24 07:00AM	Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -5.48%
Oct-17-24 08:00AM	Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium (GlobeNewswire)
Oct-16-24 04:00PM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-12-24 08:28AM	Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline (TipRanks)
Oct-11-24 08:00AM	Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity (GlobeNewswire)
Sep-14-24 03:10AM	Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis (GlobeNewswire)
Sep-10-24 08:00AM	Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference (GlobeNewswire) +8.61%
Sep-09-24 07:00AM	Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316 (GlobeNewswire)
Aug-15-24 09:40AM	Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year? (Zacks)
Aug-13-24 08:00AM	Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
Jun-21-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-05-24 09:40AM	Is Acrivon Therapeutics, Inc. (ACRV) Outperforming Other Medical Stocks This Year? (Zacks)
May-29-24 08:00AM	Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-24 09:47AM	Here's Why You Should Buy Acrivon Therapeutics (ACRV) Stock (Zacks)
May-20-24 09:40AM	Has Acrivon Therapeutics, Inc. (ACRV) Outpaced Other Medical Stocks This Year? (Zacks)
May-14-24 01:54PM	ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
May-10-24 08:50AM	Is a Surprise Coming for Acrivon Therapeutics (ACRV) This Earnings Season? (Zacks) +7.74%
Apr-29-24 07:08AM	Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral (MT Newswires) +18.20%
Apr-24-24 04:01PM	Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event (GlobeNewswire) -10.84%
Apr-16-24 08:01PM	Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316 (GlobeNewswire) +9.19%
Apr-10-24 08:00AM	Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 (GlobeNewswire) +8.00%
Apr-09-24 10:32AM	ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost (InvestorPlace) +62.77%
07:00AM	Acrivon Therapeutics Announces $130 Million Private Placement Financing (GlobeNewswire)
Mar-30-24 05:31AM	Acrivon Therapeutics Inc (ACRV) Reports Increased Annual Loss: A Detailed Look Against Analyst ... (GuruFocus.com)
Mar-28-24 12:52PM	ACRV Stock Earnings: Acrivon Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +10.60%
08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316 (GlobeNewswire)
Mar-04-24 08:00AM	Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors (GlobeNewswire) -11.40%
Feb-27-24 08:00AM	Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) +22.07%
Feb-08-24 08:00AM	Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magov evi -Liebisch, Ph.D., J.D., to Board of Directors (GlobeNewswire)
Feb-06-24 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-24 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.31%
Jan-04-24 08:00AM	Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.63%
Jan-03-24 08:00AM	Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer (GlobeNewswire)
Nov-28-23 08:00AM	Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer (GlobeNewswire)
Nov-21-23 08:00AM	Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference (GlobeNewswire) -9.02%
08:00AM	Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 08:01AM	Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) -19.19%
Oct-16-23 08:00AM	Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-28-23 04:05PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-19-23 04:32PM	Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-05-23 04:05PM	Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivons AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies (GlobeNewswire)
Aug-30-23 08:00AM	Acrivon Therapeutics to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-17-23 04:00PM	Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-23 07:00AM	Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights (GlobeNewswire) +6.81%
Aug-08-23 12:38PM	Q2 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-20-23 08:00AM	Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs (GlobeNewswire)
Jun-29-23 04:49PM	7 Up-and-Coming Stocks to Buy for the Next Decade (InvestorPlace)
Jun-22-23 04:00PM	Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors (GlobeNewswire) +5.98%
Jun-02-23 08:00AM	Acrivon Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-09-23 10:43AM	Q1 2023 Akoya Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.77%
08:00AM	Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
08:00AM	Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer (GlobeNewswire)
May-07-23 08:17AM	We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-25-23 08:00AM	Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Apr-24-23 08:00AM	Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference (GlobeNewswire)
Mar-28-23 08:00AM	Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire)
Mar-06-23 08:00AM	Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-27-23 08:00AM	Acrivon Therapeutics to Participate on a Panel at Cowens 43rd Annual Health Care Conference (GlobeNewswire) +23.94%
Feb-15-23 05:40AM	Acrivon Therapeutics, Inc. (NASDAQ:ACRV) insider upped their holding earlier this year (Simply Wall St.)
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-22-23 03:31PM	13 Cheap New Stocks To Buy (Insider Monkey)
Nov-14-22 10:16PM	Acrivon Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Blume-Jensen Peter	President and CEO	Jan 14 '26	Buy	1.68	49,000	82,124	2,095,771	Jan 16 04:02 PM
Levy Adam D.	Chief Financial Officer	Jan 14 '26	Buy	1.70	8,832	14,999	20,983	Jan 16 04:01 PM
Devroe Eric	Chief Operating Officer	Jan 13 '26	Buy	1.72	10,000	17,218	75,308	Jan 15 04:38 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 30 '25	Sale	1.41	437,881	617,412	3,403,025	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	May 01 '25	Sale	1.34	298,886	400,507	3,104,139	May 01 07:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 25 '25	Sale	1.95	1,054,669	2,056,605	4,306,189	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 29 '25	Sale	1.41	250,000	352,500	3,840,906	Apr 29 07:26 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Apr 28 '25	Sale	1.56	215,283	335,841	4,090,906	Apr 29 07:26 PM

Open in Screener

NEWT

NewtekOne Inc

Jan 21 • 04:00PM ET

13.82

+0.28 2.07 %

Financial • Banks - Regional • USA • NASD

Peers: ARCC MAIN GSBD TSLX TPVG TCPC HTGC SLRC GLAD PSEC

| Held by: IWM VTI VXF IWN SCHA VTWO FDM IWC AVSC ITOT

Index	RUT	P/E	6.22	EPS (ttm)	2.22	Insider Own	13.56%	Shs Outstand	28.88M	Perf Week	-1.29%
Market Cap	399.22M	Forward P/E	6.00	EPS next Y	2.30	Insider Trans	0.62%	Shs Float	24.97M	Perf Month	13.09%
Enterprise Value	2.16B	PEG	0.80	EPS next Q	0.68	Inst Own	41.62%	Short Float	9.72%	Perf Quarter	28.92%
Income	57.62M	P/S	1.19	EPS this Y	13.78%	Inst Trans	0.83%	Short Ratio	9.19	Perf Half Y	18.22%
Sales	335.42M	P/B	1.18	EPS next Y	3.29%	ROA	2.91%	Short Interest	2.43M	Perf YTD	21.76%
Book/sh	11.72	P/C	1.84	EPS next 5Y	7.46%	ROE	17.74%	52W High	14.91 -7.31%	Perf Year	6.14%
Cash/sh	7.51	P/FCF	11.95	EPS past 3/5Y	-19.08% -1.68%	ROIC	2.49%	52W Low	9.12 51.54%	Perf 3Y	-24.11%
Dividend Est.	0.76 (5.50%)	EV/EBITDA	12.37	Sales past 3/5Y	27.50% 24.91%	Gross Margin	76.01%	Volatility	4.31% 3.44%	Perf 5Y	-29.20%
Dividend TTM	0.76 (5.50%)	EV/Sales	6.44	EPS Y/Y TTM	25.69%	Oper. Margin	39.93%	ATR (14)	0.47	Perf 10Y	8.22%
Dividend Ex-Date	Dec 22, 2025	Quick Ratio	2.78	Sales Y/Y TTM	6.38%	Profit Margin	17.18%	RSI (14)	65.30	Recom	2.67
Dividend Gr. 3/5Y	-37.75% -18.78%	Current Ratio	2.78	EPS Q/Q	49.11%	SMA20	9.70%	Beta	1.30	Target Price	16.12
Payout	38.86%	Debt/Eq	4.99	Sales Q/Q	-19.47%	SMA50	19.58%	Rel Volume	1.69	Prev Close	13.54
Employees	591	LT Debt/Eq	4.99	Earnings	Jan 29 AMC	SMA200	22.54%	Avg Volume	264.12K	Price	13.82
IPO	Mar 17, 1980	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.80% -4.30%	Trades		Volume	439,532	Change	2.07%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-25	Resumed	B. Riley Securities	Buy	$18
Sep-04-24	Downgrade	B. Riley Securities	Buy → Neutral	$16 → $13
May-19-23	Initiated	B. Riley Securities	Buy	$15
Feb-22-23	Initiated	Piper Sandler	Neutral
Aug-08-22	Upgrade	Raymond James	Underperform → Mkt Perform
Aug-03-21	Downgrade	Raymond James	Mkt Perform → Underperform
Jun-07-21	Downgrade	Compass Point	Buy → Neutral	$33 → $38
Apr-20-21	Upgrade	Compass Point	Neutral → Buy	$30
Feb-09-21	Resumed	Keefe Bruyette	Mkt Perform	$21
Aug-11-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-19-20	Upgrade	Ladenburg Thalmann	Neutral → Buy	$13
Mar-16-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jan-08-20	Downgrade	Raymond James	Mkt Perform → Underperform
Nov-08-19	Downgrade	Raymond James	Outperform → Mkt Perform
Dec-28-18	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-24-18	Upgrade	Raymond James	Mkt Perform → Outperform
Sep-27-18	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-05-18	Downgrade	Raymond James	Outperform → Mkt Perform
May-30-17	Resumed	Keefe Bruyette	Mkt Perform
May-24-17	Downgrade	Compass Point	Buy → Neutral

Show Previous Ratings

Jan-21-26 01:03PM	NewtekOne, Inc. Closes ALP Loan Securitization with Sale of $295 Million of Rated Notes (GlobeNewswire)
Jan-12-26 08:30AM	NewtekOne, Inc. to Report Fourth Quarter 2025 Results and Host a Conference Call on Thursday, January 29, 2026 (GlobeNewswire)
07:00AM	NewtekOne, Inc. Announces Extension of Exchange Offer for its Notes due 2026 (GlobeNewswire)
Jan-08-26 08:30AM	NewtekOne, Inc. Posts Investor Day Presentation and Provides 2026 EPS Guidance Range of $2.15-$2.55 (GlobeNewswire) +5.87%
Dec-23-25 08:30AM	NewtekOne, Inc. to Host Investor/Analyst Day on January 8, 2026 (GlobeNewswire)
02:50AM	Loading…
Dec-22-25 02:50AM	Ex-IberiaBank CEO is getting the band back together (Banking Dive)
Dec-17-25 09:13AM	From 208-Year-Old Utilities to Modern BDCs: Where Safe Income Meets Growth (24/7 Wall St.)
Dec-10-25 09:38AM	NewtekOne, Inc. Declares Dividend on Series B Preferred Shares (GlobeNewswire)
09:35AM	NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Common Share (GlobeNewswire)
Dec-01-25 01:42PM	NewtekOne, Inc. Commences Exchange Offer for 2026 Notes (GlobeNewswire)
11:59AM	NewtekOne, Inc. Announces Investor/Analyst Day and Provides 4Q25 Update (GlobeNewswire)
Nov-05-25 01:47PM	Newtek Merchant Solutions Hires Justine Martin as Chief Revenue Officer (GlobeNewswire)
Oct-29-25 08:00PM	NewtekOne (NEWT) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:30PM	NewtekOne (NEWT) Q3 Earnings Surpass Estimates (Zacks)
04:26PM	NewtekOne: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Loading…
04:02PM	NewtekOne, Inc. Reports 3Q25 and Year-to-Date 2025 Basic and Diluted EPS of $0.68 and $0.67 and $1.57 and $1.54 (GlobeNewswire)
Oct-23-25 10:00AM	Analysts Estimate Axos Financial (AX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-22-25 10:00AM	NewtekOne (NEWT) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-08-25 08:30AM	NewtekOne, Inc. to Report Third Quarter 2025 Results and Host a Conference Call on Wednesday, October 29, 2025 (GlobeNewswire)
Oct-04-25 05:16PM	NewtekOne (NEWT) Secures $95M Financing from Goldman Sachs Alternatives (Insider Monkey)
Oct-01-25 08:50AM	How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings (Zacks)
Sep-30-25 09:30AM	Newtek Merchant Solutions Obtains Term Facility and Line of Credit from Goldman Sachs Alternatives (GlobeNewswire)
08:30AM	NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share (GlobeNewswire)
Sep-29-25 05:03PM	NewtekOne, Inc. Declares Dividend on Series B Preferred Shares (GlobeNewswire)
Sep-19-25 04:02PM	NewtekOne, Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 (GlobeNewswire)
Sep-17-25 12:21PM	Patriot Financial Partners, L.P. Exchanges NewtekOne, Inc. Convertible Preferred Shares for Common Equity and Makes $10 Million Incremental Investment (GlobeNewswire)
Sep-09-25 08:50AM	Despite Fast-paced Momentum, NewtekOne (NEWT) Is Still a Bargain Stock (Zacks)
Aug-25-25 08:30AM	NewtekOne, Inc. Closes Offering of Depositary Shares Each Representing 1/40th of an Interest in its Series 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (GlobeNewswire)
Aug-04-25 08:30AM	NewtekOne and Newtek Bank Unveil Real-Time, All-in-One Business Banking + Merchant Solutions in a Single Online Process (GlobeNewswire)
Jul-29-25 08:30AM	NewtekOne, Inc. Upsizes Additional Warehouse Facility to Support Growth of ALP Business (GlobeNewswire)
03:04AM	Loading…
03:04AM	NewtekOne Inc (NEWT) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Jul-28-25 05:10PM	NewtekOne (NEWT) Q2 Earnings Surpass Estimates (Zacks)
04:07PM	NewtekOne: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	NewtekOne, Inc. Reports Basic and Diluted EPS of $0.53 and $0.52 for the Three Months Ended June 30, 2025 (GlobeNewswire)
Jul-08-25 10:57AM	Sizzling Insider Buys for Your High-Yield Watchlist (MarketBeat)
Jun-25-25 08:30AM	NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share (GlobeNewswire)
Jun-18-25 08:30AM	NewtekOne, Inc. Upsizes Warehouse Facility to Support Growth of ALP Business (GlobeNewswire)
Jun-02-25 08:30AM	NewtekOne, Inc. to Report Second Quarter 2025 Results and Host a Conference Call on Monday, July 28, 2025 (GlobeNewswire)
May-07-25 10:58AM	Newtekone targets $2.10-$2.50 EPS range for 2025 with focus on technology-driven banking (Seeking Alpha)
10:57AM	NewtekOne, Inc. (NEWT) Q1 2025 Earnings Conference Call Transcript (Seeking Alpha)
08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
May-06-25 06:00PM	Compared to Estimates, NewtekOne (NEWT) Q1 Earnings: A Look at Key Metrics (Zacks)
05:25PM	NewtekOne (NEWT) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:10PM	NewtekOne, Inc. Reports Basic and Diluted EPS of $0.36 and $0.35 for the Three Months Ended March 31, 2025 (GlobeNewswire)
May-01-25 06:30PM	UMH Properties (UMH) Q1 FFO Meet Estimates (Zacks)
Apr-28-25 10:17AM	NewtekOne: A Combination Of Value And Yield (Seeking Alpha)
Apr-25-25 07:40AM	Lazard (LAZ) Q1 Earnings and Revenues Top Estimates (Zacks)
Apr-23-25 12:10PM	NewtekOne, Inc. Closes ALP Loan Securitization with Sale of $184 Million of Rated Notes (GlobeNewswire)
08:30AM	NewtekOne, Inc. Announces Peter Downs has been named President of Newtek Bank, N.A. (GlobeNewswire)
Apr-17-25 08:10AM	My Dividend Stock Portfolio: New All-Time Dividend Record In March - 100 Holdings With 15 Buys (Seeking Alpha)
Apr-14-25 08:30AM	NewtekOne, Inc. Estimates $2.0 Million of Annual Expense Savings (GlobeNewswire)
Apr-10-25 12:52PM	NewtekOne (NEWT) Surges 7.2%: Is This an Indication of Further Gains? (Zacks) -6.46%
Apr-08-25 09:00AM	NewtekOne, Inc. Announces Balance Sheet Metrics for 1Q25 and Reiterates EPS Guidance for 2025 (GlobeNewswire)
Apr-04-25 04:05PM	NewtekOne, Inc. to Report First Quarter 2025 Results on Tuesday, May 6, 2025 and Host a Conference Call on Wednesday, May 7, 2025 (GlobeNewswire) -8.77%
Mar-31-25 10:52AM	NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share (GlobeNewswire)
05:41AM	NewtekOne: 6.4% Dividend Yield From Banking Upstart Is Elevated (Seeking Alpha)
Mar-26-25 03:08PM	Golub Capital BDC's NAV, Valuation And Dividend Vs. 11 BDC Peers - Part 2 (Includes Updated Dividend Projections) (SeekingAlpha)
Mar-25-25 01:13PM	Rithm Capital Reaches Milestone With Record MSR-Backed Debt Issuance (Zacks)
Mar-20-25 11:47AM	NewtekOne, Inc. (NASDAQ:NEWT): Among the Best NASDAQ Stocks with the Lowest P/E Ratios (InsiderMonkey)
08:30AM	NewtekOne, Inc. Closes Private Offering of Senior Unsecured Notes (GlobeNewswire)
Mar-11-25 08:30AM	Newtek Merchant Solutions Hires John O'Connor as Chief Revenue Officer (GlobeNewswire)
Mar-05-25 11:28AM	Newtek Bank, N.A. Hires Vik Mahajan as Chief Investment Officer (GlobeNewswire)
Mar-03-25 08:30AM	NewtekOne, Inc. Hires Bryce Rowe as the Company's Vice President, Investor Relations (GlobeNewswire)
Feb-26-25 05:27PM	NewtekOne, Inc. Reports Full Year 2024 Earnings of $1.97 per Basic and $1.96 per Diluted Common Share (GlobeNewswire) +6.46%
Feb-18-25 08:30AM	NewtekOne, Inc. Announces Newtek Advantage Now Integrates with Intuit QuickBooks (GlobeNewswire)
Jan-21-25 08:30AM	NewtekOne, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025, After the Market Closes (GlobeNewswire)
Jan-06-25 08:30AM	Newtek Bank, N.A. Reaches Over $1.0 Billion in Deposits (GlobeNewswire)
Dec-30-24 04:35PM	NewtekOne, Inc. and Paltalk, Inc. To Hold Conference Call on January 2, 2025, To Discuss the Anticipated January 2, 2025 Closing of the Divestiture of Newtek Technology Solutions, Inc. to Paltalk, Inc. (GlobeNewswire)
Dec-16-24 08:30AM	NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share (GlobeNewswire)
Dec-10-24 01:05PM	Newtek Bank, N.A. and Apiture Honored for Most Effective Bank-Fintech Partnership in the IBSi Global FinTech Innovation Awards (GlobeNewswire)
09:00AM	Apiture and Newtek Bank Honored for Best Bank-Fintech Partnership in the IBSi Global FinTech Innovation Awards (ACCESS Newswire)
Dec-06-24 08:36AM	NewtekOne, Inc. Forecasts Originating Approximately $1.4 Billion in Business Loans in 2024 (GlobeNewswire)
Nov-18-24 08:30AM	Newtek Bank, N.A. Launches Newtek Zero-Fee Business Banking (GlobeNewswire)
Nov-14-24 12:10PM	NewtekOne, Inc.'s, CEO, Barry Sloane, Interviewed at the LD Micro Main Event XVII Investor Conference (GlobeNewswire)
Nov-06-24 04:10PM	NewtekOne, Inc. Reports Third Quarter 2024 Earnings of $0.45 per Basic and Diluted Common Share (GlobeNewswire) +10.61%
Nov-04-24 08:30AM	NewtekOne, Inc. Hires Ron Lay as Chief Technology Officer at NewtekOne, Inc. and Newtek Bank, N.A. (GlobeNewswire)
Oct-31-24 10:50AM	NewtekOne, Inc. Announces Appointment of a New Independent Director (GlobeNewswire)
Oct-25-24 10:55AM	NewtekOne, Inc. CEO, Barry Sloane, to Present at the LD Micro Main Event XVII on October 29, 2024 (GlobeNewswire)
Oct-08-24 11:16AM	Newtek Bank, N.A. Achieves 11.7% Deposit Growth in the Third Quarter 2024 (GlobeNewswire)
Oct-03-24 12:30PM	NewtekOne, Inc. Achieves 17.3% Sequential Growth in Record Total Loan Closings in the Third Quarter 2024 over the Second Quarter 2024 (GlobeNewswire)
Oct-02-24 10:51AM	NewtekOne, Inc. to Report Third Quarter 2024 Financial Results on Wednesday, November 6, 2024 After the Market Closes (GlobeNewswire)
Sep-16-24 02:45PM	NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share (GlobeNewswire)
12:44PM	NewtekOne, Inc. Closes Offering of $75.0 Million of 8.625% Fixed Rate Senior Notes Due 2029 (GlobeNewswire)
Sep-05-24 08:30AM	NewtekOne, Inc. Reconfirms its 2024 Annual EPS Forecast in a Range of $1.85 to $2.05 per Basic and Diluted Common Share (GlobeNewswire)
Sep-03-24 08:30AM	NewtekOne, Inc. Hires Andrew Kaplan as Chief Strategy Officer (GlobeNewswire)
Aug-28-24 10:05AM	NewtekOne, Inc. CEO, Barry Sloane, to Attend the Raymond James 2024 U.S. Banking and Banking on Tech Conference September 4-5, 2024 (GlobeNewswire)
Aug-12-24 10:20AM	NewtekOne Enters into Agreement to Sell Newtek Technology Solutions, Inc. (GlobeNewswire)
Aug-05-24 04:05PM	NewtekOne, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-24-24 10:50AM	NewtekOne, Inc. Closes $154,320,000 Alternative Business Loan Backed Securitization (GlobeNewswire)
Jul-01-24 08:45AM	NewtekOne, Inc. to Report Second Quarter 2024 Financial Results on Monday, August 5, 2024 After the Market Closes (GlobeNewswire)
Jun-27-24 08:30AM	NewtekOne, Inc. Declares a Quarterly Dividend of $0.19 per Share (GlobeNewswire)
Jun-10-24 08:30AM	NewtekOne, Inc. CEO, Barry Sloane, to Attend the 25th Annual KBW Community Bank Investor Conference July 30-31, 2024 (GlobeNewswire)
Jun-06-24 09:15AM	NewtekOne, Inc. To Webcast its Analyst and Investor Day on Thursday, June 13, 2024 on its Corporate Website (GlobeNewswire)
Jun-05-24 11:55AM	NewtekOne, Inc. Completes Offering of $71.875 Million of 8.50% Fixed Rate Senior Notes Due 2029 (GlobeNewswire)
May-13-24 11:00AM	NewtekOne, Inc. To Hold Analyst and Investor Day, Thursday, June 13, 2024 at its Headquarters in Boca Raton, Florida (GlobeNewswire)
May-08-24 04:19PM	Newtek Business Services Corp. (NASDAQ:NEWT) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:13AM	NewtekOne Inc (NEWT) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations and ... (GuruFocus.com)
May-06-24 04:05PM	NewtekOne, Inc. Reports First Quarter 2024 Financial Results (GlobeNewswire) +11.28%
May-02-24 09:00AM	"Apiture Innovator" Awards Announced at Apiture Accelerate 2024 Conference (ACCESSWIRE)
Apr-23-24 08:30AM	NewtekOne, Inc. CEO, Barry Sloane, to Attend the B. Riley Securities 24th Institutional Investor Conference May 22-23, 2024 (GlobeNewswire)

NewtekOne, Inc. is a financial holding company, which engages in the provision of business and financial solutions. Its brands include Newtek Bank, Newtek Lending, Newtek Payments, Newtek Insurance, Newtek Payroll, and Newtek Technology. The company was founded by Barry Sloane in 1998 and is headquartered in Boca Raton, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Razon-Feingold Halli	SVP, Human Resources & CAO	Jan 14 '26	Buy	13.91	1,258	17,499	22,915	Jan 16 09:07 AM
Schwartz Michael Adam	Chief Legal Officer	Jan 14 '26	Buy	13.91	2,247	31,256	49,713	Jan 16 09:02 AM
DeMaria Frank M	Cheif Financial Officer	Jan 14 '26	Buy	13.91	1,556	21,644	35,220	Jan 16 08:59 AM
SLOANE BARRY	President, Chairman & CEO	Jan 14 '26	Buy	13.91	3,595	50,006	1,194,180	Jan 16 08:56 AM
Zink Gregory L	Director	Dec 15 '25	Buy	12.06	500	6,030	37,707	Dec 15 09:43 AM
SALUTE RICHARD J	Director	Dec 08 '25	Buy	11.28	900	10,152	44,505	Dec 08 11:57 AM
Brunet Craig Jeffry	Director	Dec 05 '25	Buy	11.31	789	8,925	5,572	Dec 08 08:33 AM
Zink Gregory L	Director	Nov 03 '25	Buy	10.43	1,000	10,430	37,207	Nov 04 07:19 AM
SLOANE BARRY	Chairman & CEO	Nov 03 '25	Buy	10.22	10,000	102,170	1,212,459	Nov 03 10:44 AM
SALUTE RICHARD J	Director	Aug 01 '25	Buy	11.24	2,100	23,611	43,605	Aug 04 08:29 AM
SLOANE BARRY	Chairman & CEO	Jun 20 '25	Buy	10.39	2,000	20,785	1,202,459	Jun 23 08:32 AM
Downs Peter Mathison	President - Newtek Bank, N.A.	May 29 '25	Buy	11.07	500	5,535	94,185	Jun 02 08:32 AM
SLOANE BARRY	Chairman & CEO	May 29 '25	Buy	10.86	10,000	108,611	1,200,459	May 29 01:22 PM
SLOANE BARRY	Chairman & CEO	May 19 '25	Buy	11.23	10,000	112,326	1,190,459	May 20 08:31 AM
DeMaria Frank M	EVP, Chief Financial Officer	May 16 '25	Buy	11.22	500	5,610	33,526	May 19 08:29 AM
Downs Peter Mathison	President - Newtek Bank, N.A.	May 15 '25	Buy	11.06	500	5,530	93,685	May 15 12:06 PM
SLOANE BARRY	Chairman & CEO	May 13 '25	Buy	11.61	10,000	116,126	1,180,459	May 14 08:30 AM
SALUTE RICHARD J	Director	May 12 '25	Buy	11.07	5,000	55,338	39,222	May 13 08:59 AM
Brunet Craig Jeffry	Director	May 12 '25	Buy	10.94	1,000	10,944	2,500	May 12 12:21 PM
Zink Gregory L	Director	May 09 '25	Buy	10.39	2,000	20,780	33,924	May 12 09:51 AM
Zink Gregory L	Director	Mar 21 '25	Buy	12.34	500	6,170	31,924	Mar 24 08:56 AM
Brunet Craig Jeffry	Director	Mar 20 '25	Buy	12.48	500	6,240	1,500	Mar 21 09:00 AM

AIRJ AirJoule Technologies Corp daily Stock Chart

Peers: HON BA GD TXT LMT NOC SPR DCO HXL TDG

| Held by: VTI WGMI IWM VXF IWN VTWO SCHA IWC VTWV RSSL

Index	RUT	P/E	-	EPS (ttm)	-0.02	Insider Own	62.74%	Shs Outstand	60.54M	Perf Week	-9.32%
Market Cap	240.60M	Forward P/E	-	EPS next Y	-0.29	Insider Trans	1.51%	Shs Float	24.90M	Perf Month	6.19%
Enterprise Value	214.72M	PEG	-	EPS next Q	-0.07	Inst Own	10.39%	Short Float	6.13%	Perf Quarter	-35.14%
Income	-0.93M	P/S	-	EPS this Y	-96.03%	Inst Trans	18.39%	Short Ratio	3.47	Perf Half Y	-23.40%
Sales	0.00M	P/B	0.76	EPS next Y	-282.81%	ROA	-0.25%	Short Interest	1.53M	Perf YTD	-8.63%
Book/sh	4.73	P/C	9.25	EPS next 5Y	-	ROE	-0.34%	52W High	9.31 -61.33%	Perf Year	-60.18%
Cash/sh	0.39	P/FCF	-	EPS past 3/5Y	- -	ROIC	-0.32%	52W Low	2.61 37.93%	Perf 3Y	-63.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.28% 9.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-100.27%	Oper. Margin	-	ATR (14)	0.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	14.15	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	14.15	EPS Q/Q	-110.87%	SMA20	-7.98%	Beta	0.46	Target Price	8.94
Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-2.79%	Rel Volume	2.30	Prev Close	3.31
Employees	17	LT Debt/Eq	0.00	Earnings	Nov 13 AMC	SMA200	-19.71%	Avg Volume	440.37K	Price	3.60
IPO	Feb 01, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.65% -	Trades		Volume	989,043	Change	8.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-25	Initiated	Ladenburg Thalmann	Buy
Feb-24-25	Initiated	Alliance Global Partners	Buy	$11
Dec-20-24	Initiated	H.C. Wainwright	Buy	$12

Jan-20-26 08:00AM	AirJoule Technologies Commissions Atmospheric Water Harvesting System at Arizona State University for Independent Academic Evaluation (GlobeNewswire)
Jan-14-26 07:30AM	AirJoule Technologies Announces Pricing of $20 Million Public Offering of Class A Common Stock (GlobeNewswire) -13.60%
Jan-13-26 04:54PM	AirJoule Technologies Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Jan-08-26 08:00AM	AirJoule Technologies Begins Net Zero Innovation Hub for Data Centers Program and Advances Commercial Deployment with Google, Microsoft, and Industry Leaders (GlobeNewswire)
Jan-06-26 09:40AM	Is AirJoule Technologies Corporation (AIRJ) Outperforming Other Business Services Stocks This Year? (Zacks)
08:00AM	Loading…
Dec-19-25 08:00AM	AirJoule Technologies Partners with Red Dot Ranch to Advance Residential Off-Grid Water Solutions in California's Coastal Communities (GlobeNewswire)
Dec-10-25 12:58PM	RR Stock Soars 114% in 6 Months: Time to Chase or Hold Back? (Zacks)
Dec-02-25 08:00AM	AirJoule Technologies Identifies Nexus Data Centers as AI Hyperscale Developer and Advances Existing MOU Toward First Deployment of Onsite Water Purchase Agreement Using Waste Heat from Planned Nexus Data Centers Campus Under Construction in Hubbard, Texas (GlobeNewswire)
Nov-14-25 04:03PM	AirJoule Technologies Corp (AIRJ) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com) -6.42%
Nov-13-25 04:05PM	AirJoule Technologies (NASDAQ: AIRJ) Announces Third Quarter 2025 Results and Provides Business Update (GlobeNewswire) -8.01%
Nov-07-25 08:00AM	AirJoule Technologies Schedules Release of Third Quarter 2025 Results and Conference Call (GlobeNewswire)
Oct-09-25 04:05PM	AirJoule Technologies Applauds 2025 Nobel Prize in Chemistry Winners for Foundational Work on Metal-Organic Frameworks (GlobeNewswire) -7.24%
Oct-07-25 08:30AM	AirJoule Technologies and the U.S. Army Engineer Research and Development Center to Collaborate on Atmospheric Water Generation Using Waste Heat (GlobeNewswire)
Sep-25-25 08:30AM	AirJoule Selected as Winner of Net Zero Innovation Hub Competition and Invited to Collaborate with Google, Microsoft, and other Industry Leaders on Water-Sustainable Data Centers (GlobeNewswire)
Sep-16-25 08:30AM	AirJoule Technologies Delivers Groundbreaking "Waste Heat to Water" System to Hubbard, Texas (GlobeNewswire)
11:21AM	Loading…
Sep-04-25 11:21AM	MVST's Expansion in China: How Does This Play for Customer Demand? (Zacks)
Aug-15-25 01:01PM	AirJoule Technologies Corp (AIRJ) Q2 2025 Earnings Call Highlights: Strategic Collaborations ... (GuruFocus.com)
Aug-13-25 04:05PM	AirJoule Technologies Announces Second Quarter 2025 Results (GlobeNewswire) +5.46%
07:12AM	Texas city pioneers tech that uses waste heat to generate drinking water (SmartCities Dive)
Aug-07-25 08:30AM	AirJoule Technologies to Showcase its Groundbreaking Platform for "Waste Heat to Water" Project in Texas, Unleashing the Power of Water from Air (GlobeNewswire) +6.62%
Aug-04-25 08:30AM	AirJoule Technologies Cuts the Ribbon at Delaware Manufacturing Facility (GlobeNewswire) +5.28%
Jul-29-25 08:30AM	AirJoule Technologies Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jul-09-25 12:25PM	Can MVST's Dive Into Electric Boats Create Waves in Its Top Line? (Zacks)
Jun-26-25 08:00AM	AirJoule Technologies Announces Two New Appointments to its Board of Directors (GlobeNewswire)
Jun-18-25 09:20AM	AirJoule Technologies enters MOU with hyperscale data center developor (TipRanks)
Jun-17-25 09:00AM	AirJoule Technologies Announces Memorandum of Understanding with Data Center Developer to Advance Onsite Water Production Using Waste Heat (GlobeNewswire)
Jun-09-25 08:00AM	AirJoule Technologies Set to Join Russell 3000 Index (GlobeNewswire)
May-24-25 07:05AM	AirJoule transferred with Buy rating at Alliance Global Partners (TipRanks)
May-13-25 12:00PM	All You Need to Know About AirJoule Technologies Corporation (AIRJ) Rating Upgrade to Strong Buy (Zacks)
May-12-25 04:50PM	AirJoule Technologies Announces First Quarter 2025 Results (GlobeNewswire) -7.59%
04:01PM	Loading…
May-06-25 04:01PM	AirJoule Technologies Schedules Release of First Quarter 2025 Results and Conference Call (GlobeNewswire)
May-05-25 11:43AM	Coherent Pre-Q3 Earnings: Buy or Sell the Stock Ahead of Results? (Zacks) -11.54%
Apr-24-25 09:00AM	AirJoule Technologies Announces $15 Million Investment Anchored by GE Vernova (GlobeNewswire)
Apr-10-25 08:54AM	AirJoule Technologies (AIRJ): Strong Industry, Solid Earnings Estimate Revisions (Zacks)
Apr-08-25 08:30AM	AirJoule Technologies Announces Collaboration with Arizona State University to Advance Atmospheric Water Harvesting in Low Humidity Environments (GlobeNewswire)
Apr-02-25 09:35AM	After Plunging -36.69% in 4 Weeks, Here's Why the Trend Might Reverse for AirJoule Technologies Corporation (AIRJ) (Zacks)
Mar-29-25 07:13PM	Why AirJoule Technologies Corp (AIRJ) Is Plunging in 2025? (Insider Monkey)
Mar-26-25 05:40PM	AirJoule Technologies reports FY24 EPS $4.03 vs. (30c) last year (TipRanks) -26.73% -5.29%
Mar-25-25 05:09PM	AirJoule Technologies Announces Fourth Quarter and Full Year 2024 Results and Groundbreaking Performance of AirJoule System (GlobeNewswire)
08:30AM	AirJoule Technologies Schedules Release of Fourth Quarter and Full Year 2024 Results and Conference Call (GlobeNewswire)
Nov-13-24 04:01PM	AirJoule Technologies Announces Third Quarter 2024 Results (GlobeNewswire)
08:50AM	Montana Technologies Announces Name Change to AirJoule Technologies (GlobeNewswire)
Nov-12-24 09:17AM	Montana Technologies Schedules Third Quarter 2024 Earnings Release and Conference Call (GlobeNewswire)
Oct-10-24 08:30AM	Montana Technologies Signs Abu Dhabi Sustainable Finance Declaration and Attends WETEX in Dubai (GlobeNewswire)
Sep-25-24 09:20AM	Montana Technologies Establishes International Office in the United Arab Emirates (GlobeNewswire)
Sep-04-24 08:32AM	Montana Technologies Announces Memorandum of Understanding with Clairity Technology to Deploy AirJoule in Support of Direct Air Capture Carbon Dioxide Removal Projects (GlobeNewswire) +8.17%
Aug-23-24 08:30AM	Montana Technologies Announces Second Quarter 2024 Results (GlobeNewswire)
Aug-15-24 09:00AM	Montana Technologies Announces Memorandum of Understanding with TenX Investment to Deploy AirJoule for Water Security and Sustainability in the United Arab Emirates (GlobeNewswire) -5.73%
Aug-13-24 08:29AM	Montana Technologies to Restate Previously Issued Financial Statements (GlobeNewswire)
Aug-08-24 09:00AM	Montana Technologies announces agreement with Climate Impact Corporation to collaborate on atmospheric water generation for renewable hydrogen production (GlobeNewswire)
Jun-11-24 05:09PM	Montana Technologies Announces Private Placement Financing (Business Wire) -12.80% +8.08%
May-20-24 05:28PM	Montana Technologies Announces First Quarter 2024 Results (PR Newswire) +5.52%
May-07-24 04:30PM	Montana Technologies Corp. Expands Management Team with Key Appointments (PR Newswire)
May-01-24 08:00AM	Montana Technologies Corp. Announces Addition to Board of Directors and Names Chairman (PR Newswire)
Mar-14-24 03:43PM	Power & Digital Infrastructure Acquisition II Corp. (XPDB) Announces Closing of Business Combination with Montana Technologies LLC (PR Newswire) +5.55%

AirJoule Technologies Corp. operates as a thermal energy and water harvesting technology company. It provides efficient and sustainable air conditioning and pure water from air through its transformational AirJoule technology. The company was founded on March 14, 2024 and is headquartered in Ronan, MT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JORE MATTHEW B	Chief Executive Officer	Jan 15 '26	Buy	3.25	7,692	24,999	7,718,123	Jan 20 08:40 AM
EILERS PATRICK C	Executive Chairman	Jan 15 '26	Buy	3.25	76,923	250,000	1,860,518	Jan 20 08:38 AM
Porter Stuart D	Director	Jan 15 '26	Buy	3.25	153,846	500,000	776,879	Jan 20 08:34 AM
Murphy Thomas Edward	Director	Dec 10 '25	Buy	2.86	17,500	50,113	17,500	Dec 12 06:34 PM
Murphy Thomas Edward	Director	Dec 12 '25	Buy	3.40	14,450	49,130	31,950	Dec 12 06:34 PM
Pang Stephen S.	Chief Financial Officer	Dec 10 '25	Buy	2.95	2,169	6,399	18,990	Dec 10 08:20 PM
JORE MATTHEW B	Chief Executive Officer	Dec 09 '25	Buy	2.84	5,200	14,768	7,708,652	Dec 10 08:18 PM
JORE MATTHEW B	Chief Executive Officer	Dec 08 '25	Buy	2.77	3,521	9,753	7,703,452	Dec 10 08:18 PM
JORE MATTHEW B	Chief Executive Officer	Dec 10 '25	Buy	2.95	1,779	5,248	7,710,431	Dec 10 08:18 PM
Porter Stuart D	Director	Dec 10 '25	Buy	2.95	264,150	779,242	623,033	Dec 10 08:10 PM
Porter Stuart D	Director	Dec 09 '25	Buy	2.84	46,800	132,912	358,883	Dec 10 08:10 PM
Porter Stuart D	Director	Dec 08 '25	Buy	2.77	31,695	87,795	312,083	Dec 10 08:10 PM
Gutke Jeff	Chief Administrative Officer	Jun 06 '25	Option Exercise	0.00	6,250	0	101,443	Jun 10 06:50 PM
Gutke Jeff	Chief Administrative Officer	Jun 09 '25	Sale	4.23	1,605	6,790	99,838	Jun 10 06:50 PM
Pang Stephen S.	Chief Financial Officer	Jun 06 '25	Option Exercise	0.00	23,125	0	23,125	Jun 10 06:49 PM
Pang Stephen S.	Chief Financial Officer	Jun 09 '25	Sale	4.23	7,635	32,298	15,490	Jun 10 06:49 PM
EILERS PATRICK C	Executive Chairman	Jun 06 '25	Option Exercise	0.00	6,250	0	1,785,526	Jun 10 06:47 PM
EILERS PATRICK C	Executive Chairman	Jun 09 '25	Sale	4.23	1,931	8,169	1,783,595	Jun 10 06:47 PM
JORE MATTHEW B	Chief Executive Officer	Jun 06 '25	Option Exercise	0.00	12,500	0	7,703,796	Jun 10 06:46 PM
JORE MATTHEW B	Chief Executive Officer	Jun 09 '25	Sale	4.23	3,865	16,350	7,699,931	Jun 10 06:46 PM
Zaatari Marwa	Director	May 29 '25	Option Exercise	0.00	5,400	0	5,400	Jun 02 08:43 PM
Porter Stuart D	Director	May 29 '25	Option Exercise	0.00	5,400	0	280,388	Jun 02 08:40 PM
Derham Kyle	Director	May 29 '25	Option Exercise	0.00	5,400	0	5,400	Jun 02 08:37 PM
Dabbar Paul	Director	May 29 '25	Option Exercise	0.00	10,800	0	105,407	Jun 02 08:36 PM
Baucus Max	Director	May 29 '25	Option Exercise	0.00	5,400	0	52,997	Jun 02 08:32 PM
Agrawal Ajay	Director	May 29 '25	Option Exercise	0.00	5,400	0	5,400	Jun 02 08:31 PM
Gutke Jeff	Chief Administrative Officer	Feb 25 '25	Option Exercise	0.12	63,579	7,629	75,579	Feb 27 04:54 PM

Open in Screener

YORW

York Water Co

Jan 21 • 04:00PM ET

33.64

+0.20 0.60 %

Utilities • Utilities - Regulated Water • USA • NASD

Peers: AWK AWR WTRG CWT HTO ARTNA MSEX CWCO PNR BMI

| Held by: IFRA VTI IWM SMDV VXF IWN VPU VIG PHO DES

Index	RUT	P/E	24.17	EPS (ttm)	1.39	Insider Own	1.18%	Shs Outstand	14.43M	Perf Week	1.97%
Market Cap	485.59M	Forward P/E	21.29	EPS next Y	1.58	Insider Trans	0.70%	Shs Float	14.26M	Perf Month	-1.38%
Enterprise Value	712.91M	PEG	3.33	EPS next Q	0.32	Inst Own	57.65%	Short Float	3.03%	Perf Quarter	3.64%
Income	20.03M	P/S	6.32	EPS this Y	-4.93%	Inst Trans	0.99%	Short Ratio	5.26	Perf Half Y	6.22%
Sales	76.88M	P/B	2.04	EPS next Y	17.04%	ROA	3.11%	Short Interest	0.43M	Perf YTD	5.65%
Book/sh	16.49	P/C	-	EPS next 5Y	6.39%	ROE	8.58%	52W High	36.48 -7.79%	Perf Year	7.44%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	2.94% 4.99%	ROIC	4.31%	52W Low	29.68 13.34%	Perf 3Y	-25.95%
Dividend Est.	-	EV/EBITDA	16.99	Sales past 3/5Y	10.79% 7.76%	Gross Margin	55.27%	Volatility	1.93% 1.78%	Perf 5Y	-27.98%
Dividend TTM	0.89 (2.63%)	EV/Sales	9.27	EPS Y/Y TTM	-5.82%	Oper. Margin	36.41%	ATR (14)	0.62	Perf 10Y	35.15%
Dividend Ex-Date	Dec 31, 2025	Quick Ratio	0.95	Sales Y/Y TTM	3.63%	Profit Margin	26.06%	RSI (14)	60.94	Recom	1.00
Dividend Gr. 3/5Y	3.80% 3.96%	Current Ratio	1.15	EPS Q/Q	5.36%	SMA20	3.14%	Beta	0.72	Target Price	41.00
Payout	60.11%	Debt/Eq	0.96	Sales Q/Q	3.28%	SMA50	3.34%	Rel Volume	0.74	Prev Close	33.44
Employees	127	LT Debt/Eq	0.95	Earnings	Nov 06 BMO	SMA200	4.73%	Avg Volume	81.98K	Price	33.64
IPO	May 03, 1999	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.16% -3.04%	Trades		Volume	63,175	Change	0.60%

Date	Action	Analyst	Rating Change	Price Target Change
May-09-19	Upgrade	Janney	Neutral → Buy	$36 → $37
Mar-13-19	Downgrade	Janney	Buy → Neutral
Jan-18-19	Initiated	Janney	Buy
Mar-08-18	Upgrade	Hilliard Lyons	Underperform → Neutral
Feb-03-15	Upgrade	Boenning & Scattergood	Neutral → Outperform
Oct-13-11	Initiated	Boenning & Scattergood	Neutral
Mar-09-11	Upgrade	Brean Murray	Hold → Buy	$20
Dec-10-10	Downgrade	Brean Murray	Buy → Hold
Apr-27-09	Initiated	Brean Murray	Buy	$19
Jul-25-08	Upgrade	Janney Mntgmy Scott	Neutral → Buy

Jan-16-26 06:43AM	3 Dividend Champions to Buy and Hold for Decades (Motley Fool)
Jan-05-26 04:26AM	10 Magnificent Stocks That Can Make You Richer in 2026 (Motley Fool)
Dec-28-25 07:35AM	1 Income Stock I'd Buy Before Dividend Powerhouse York Water in 2026 (Motley Fool)
Dec-17-25 09:13AM	From 208-Year-Old Utilities to Modern BDCs: Where Safe Income Meets Growth (24/7 Wall St.)
Dec-15-25 08:08AM	York Water Has Raised Its Dividend for 13 Years and the Streak Looks Secure (24/7 Wall St.)
03:06AM	Loading…
Dec-03-25 03:06AM	Wall Street's Greatest Dividend Stock -- Which 99% of Investors Have No Clue Exists -- Makes for a Screaming Buy in 2026 (Motley Fool)
Nov-06-25 10:40AM	York Water (YORW) Q3 Earnings Top Estimates (Zacks)
09:38AM	York Water: Q3 Earnings Snapshot (Associated Press Finance)
09:30AM	The York Water Company Reports 3rd Quarter and Nine Months Earnings (GlobeNewswire)
Nov-04-25 06:20PM	Essential Utilities (WTRG) Q3 Earnings Beat Estimates (Zacks)
Oct-08-25 08:05AM	Here's Why You Should Add GWRS Stock to Your Portfolio Right Now (Zacks)
Oct-05-25 03:14PM	Why The York Water Company (YORW) Deserves its Spot Among Dividend Champions (Insider Monkey)
Sep-24-25 10:17AM	CWT or YORW: Which Water Supply Stock Promises Greater Returns? (Zacks)
Sep-23-25 03:51AM	3 Magnificent Stocks I'm Close to Buying, Even Amid a Historically Pricey Stock Market (Motley Fool)
Sep-08-25 05:09PM	What Makes York Water (YORW) a New Buy Stock (Zacks)
03:51AM	Loading…
Sep-04-25 03:51AM	Wall Street's Greatest Dividend Stock Makes for a Screaming Buy in September -- and It's a Company 99% of Investors Have Likely Never Heard of Before (Motley Fool)
Aug-29-25 12:36PM	Zacks Industry Outlook Highlights California Water Service, The York Water and Global Water Resources (Zacks)
Aug-27-25 01:00PM	3 Stocks to Watch From the Prospering Water Supply Industry (Zacks)
Aug-12-25 03:05PM	York Water (YORW) Beats Q2 Earnings and Revenue Estimates (Zacks)
02:08PM	York Water: Q2 Earnings Snapshot (Associated Press Finance)
11:47AM	The York Water Company Reports 2nd Quarter and Six Months Earnings (GlobeNewswire)
Aug-11-25 06:55PM	Ballard Power Systems (BLDP) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-07-25 09:10AM	Sempra (SRE) Q2 Earnings Top Estimates (Zacks)
Aug-06-25 07:05PM	American States Water (AWR) Q2 Earnings and Revenues Lag Estimates (Zacks)
Jul-31-25 06:15PM	Essential Utilities (WTRG) Tops Q2 Earnings and Revenue Estimates (Zacks)
03:51AM	Wall Street's Greatest Dividend Stock Hasn't Been This Cheap in Over a Decade -- but Are Investors Paying Attention? (Motley Fool)
May-30-25 10:00AM	The York Water Company Files a Rate Request Based on $145 Million in Investment (GlobeNewswire)
May-06-25 10:45AM	York Water (YORW) Lags Q1 Earnings and Revenue Estimates (Zacks)
09:39AM	York Water: Q1 Earnings Snapshot (Associated Press Finance)
09:30AM	The York Water Company Reports Three Months Earnings (GlobeNewswire)
06:25PM	Loading…
Apr-28-25 06:25PM	SJW (SJW) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
11:17AM	Is The York Water Company (YORW) Among the Most Profitable Utility Stocks to Buy Now? (Insider Monkey)
Apr-12-25 01:27AM	Dividend Champion, Contender, And Challenger Highlights: Week Of April 13 (Seeking Alpha)
Apr-04-25 07:47AM	Small-Cap Dividend Stocks: Hidden Gems Or High-Risk Plays? - Top U.S. And Canadian Ones (Seeking Alpha)
Apr-01-25 10:03AM	The York Water Company (YORW): Among Stocks Insiders Were Buying In Q1 2025 (Insider Monkey)
Mar-30-25 12:47PM	York Water: Tap Into This Dividend Aristocrat For Recession-Proof Income (Seeking Alpha)
Mar-27-25 03:59PM	The York Water Company (YORW): Among Dividend Zombies to Invest in (InsiderMonkey)
Mar-07-25 04:06AM	The Nasdaq Is Falling: 4 of the Safest Stocks to Buy Right Now (Motley Fool)
Mar-05-25 11:45AM	This is Why York Water (YORW) is a Great Dividend Stock (Zacks)
Mar-04-25 10:45AM	York Water (YORW) Misses Q4 Earnings and Revenue Estimates (Zacks)
09:49AM	York Water: Q4 Earnings Snapshot (Associated Press Finance)
09:30AM	The York Water Company Reports 2024 Annual and Fourth Quarter Results (GlobeNewswire)
Mar-02-25 09:24PM	Want Decades of Passive Income? 3 Stocks to Buy Right Now. (Motley Fool)
Feb-28-25 05:06AM	Wall Street's Greatest Dividend Stock Just Made History Again -- and 99.9% of Investors Have Never Heard of This Small-Cap Company (Motley Fool)
Feb-21-25 03:28PM	The York Water Company (YORW): Among the Worst Performing Utilities Stocks to Buy According to Analysts (Insider Monkey)
Feb-07-25 01:34PM	Is The York Water Company (YORW) Among the Small Cap Stocks Insiders Are Buying Recently? (Insider Monkey)
Jan-18-25 04:06AM	Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade (Motley Fool)
Dec-17-24 10:15AM	3 Dividend Stocks Down 2%, 7%, and 10% to Buy Before the New Year (Motley Fool)
Nov-07-24 10:40AM	York Water (YORW) Q3 Earnings Match Estimates (Zacks)
09:37AM	York Water: Q3 Earnings Snapshot (Associated Press Finance)
09:30AM	York Water Company Reports 3rd Quarter and Nine Months Earnings (GlobeNewswire)
Aug-27-24 05:06AM	Meet Wall Street's Safest Dividend Stock: A Small-Cap Company Few Investors Know Exists (Motley Fool)
Aug-02-24 10:40AM	York Water (YORW) Misses Q2 Earnings and Revenue Estimates (Zacks)
09:35AM	York Water: Q2 Earnings Snapshot (Associated Press Finance)
09:30AM	York Water Company Reports 2nd Quarter and Six Months Earnings (GlobeNewswire)
Jun-23-24 04:54PM	Is The York Water Company (YORW) the Best Dividend Zombie to Buy Right Now? (Insider Monkey)
01:23PM	10 Dividend Zombies and Kings with Longest Dividend Payouts (Insider Monkey)
Jun-17-24 10:06AM	Here's How Many Shares Of New York Water Co You Need To Earn $500 Per Month In Dividends (Benzinga)
Jun-12-24 07:10AM	The 3 Best Water Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 05:21AM	3 No-Brainer Stocks to Buy With $200 Right Now (Motley Fool)
May-27-24 12:13PM	7 Water Stocks to Buy Now: May 2024 (InvestorPlace)
May-25-24 02:56AM	3 Dividend Stocks That Are Well Positioned to Provide a Lifetime of Passive Income (Motley Fool)
May-22-24 06:00AM	The Dividend Survival Kit: 7 Stocks Under $50 to Buy for Lifelong Income (InvestorPlace)
May-16-24 09:15AM	3 Utilities Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
May-09-24 09:15AM	ACNB Corporation Announces Election of Alexandra Chiaruttini to Board of Directors (GlobeNewswire)
May-07-24 10:57PM	YORW Stock Earnings: The York Water Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
10:40AM	York Water (YORW) Q1 Earnings and Revenues Top Estimates (Zacks)
09:37AM	York Water: Q1 Earnings Snapshot (Associated Press Finance)
09:30AM	The York Water Company Reports Three Months Earnings (GlobeNewswire)
Apr-27-24 07:45AM	The Top 3 Utilities Stocks to Buy in April 2024 (InvestorPlace)
Apr-24-24 09:35AM	Latest Insider Trading Activity: 11 Stocks Executives and Directors are Buying (Insider Monkey)
Apr-19-24 05:21AM	Time to Pounce: 2 Superb Utility Stocks That Haven't Been This Cheap in at Least 10 Years (Motley Fool)
Apr-16-24 09:01AM	Reasons to Add The York Water (YORW) to Your Portfolio Now (Zacks)
Apr-15-24 07:43AM	16 Best Dividend Stocks of All Time (Insider Monkey)
Apr-10-24 01:48PM	3 Water Stocks to Snap Up Before the Next Shortage (InvestorPlace)
04:41AM	3 No-Brainer Stocks to Buy With $50 Right Now (Motley Fool)
Mar-15-24 09:01AM	3 Stocks That Have Paid Dividends for Over 100 Years (InvestorPlace)
Mar-14-24 08:25AM	Reasons to Add York Water (YORW) to Your Portfolio Right Now (Zacks)
Mar-12-24 05:21AM	Meet the Unknown Small-Cap Company That's Been Paying a Dividend for at Least 66 Years Longer Than Coca-Cola, ExxonMobil, and Eli Lilly (Motley Fool)
Mar-05-24 11:52PM	YORW Stock Earnings: The York Water Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
10:02AM	The York Water Co (YORW) Announces Increased Earnings and Revenue in 2023 (GuruFocus.com)
09:49AM	York Water: Q4 Earnings Snapshot (Associated Press Finance)
09:33AM	The York Water Company Reports 2023 Annual And Fourth Quarter Results (GlobeNewswire)
Mar-04-24 05:35PM	3 Stocks to Buy at 52-Week Lows: March 4 Edition (InvestorPlace)
Feb-25-24 12:43PM	20 Countries with the Most Freshwater Resources (Insider Monkey)
Jan-30-24 05:21AM	Wall Street's Greatest Dividend Stock Just Made History Again, and 99% of Investors Probably Don't Realize It Exists (Motley Fool)
Jan-26-24 01:54PM	Is 2024 the Year for Utilities Stocks? 3 Top Sector Picks (InvestorPlace)
Dec-28-23 09:21AM	Reasons to Add The York Water (YORW) to Your Portfolio Now (Zacks)
Dec-19-23 05:00PM	Forever Favorites: 7 Dividend Stocks to Buy and Never Sell (InvestorPlace)
Dec-18-23 02:30PM	12 High Growth Utility Stocks to Buy (Insider Monkey)
Dec-14-23 05:21AM	2 Utility Stocks to Buy Hand Over Fist in 2024 and 1 to Avoid Like the Plague (Motley Fool)
Dec-05-23 10:25AM	11 Best Water Stocks To Buy (Insider Monkey)
Nov-29-23 05:21AM	3 No-Brainer Stocks to Buy With $100 Right Now (Motley Fool)
Nov-17-23 11:18AM	Reasons to Add The York Water (YORW) to Your Portfolio Now (Zacks)
Nov-03-23 02:54PM	The York Water Co (YORW) Reports Increased Earnings for Q3 and First Nine Months of 2023 (GuruFocus.com)
10:36AM	York Water: Q3 Earnings Snapshot (Associated Press Finance)
10:14AM	York Water Company Reports 3rd Quarter And Nine Months Earnings (GlobeNewswire)
Oct-23-23 11:45AM	York Water (YORW) Could Be a Great Choice (Zacks)
Oct-06-23 11:45AM	York Water (YORW) Could Be a Great Choice (Zacks)
Oct-03-23 06:48PM	Get Paid to Invest: 3 Dividend Stocks to Buy for Income (InvestorPlace)

The York Water Co. engages in impounding, purifying, and distribution of drinking water. It owns and operates wastewater collection systems and wastewater treatment systems. The company was founded on February 23, 1816 and is headquartered in York, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Snyder Mark S	VP- Engineering	Jan 16 '26	Buy	30.45	11	350	4,531	Jan 16 03:18 PM
Scarpato Matthew J	Chief Operating Officer	Jan 16 '26	Buy	30.45	92	2,800	964	Jan 16 03:15 PM
Poff Matthew E	Chief Financial Officer	Jan 16 '26	Buy	30.45	5	140	8,212	Jan 16 03:13 PM
Hand Joseph Thomas	President & CEO	Jan 16 '26	Buy	30.45	279	8,500	39,872	Jan 16 03:09 PM
Grimm Ashley M	VP- Human Resources	Jan 16 '26	Buy	30.45	14	420	335	Jan 16 03:03 PM
Chiaruttini Alexandra C	CAO & General Counsel	Jan 16 '26	Buy	30.45	46	1,400	4,879	Jan 16 02:59 PM
Becker Suzanne M	VP- Customer Service	Jan 16 '26	Buy	30.45	46	1,400	77	Jan 16 02:30 PM
Yanavitch William T. II	Director	Dec 22 '25	Buy	33.72	44	1,500	44	Dec 23 11:12 AM
Hand Joseph Thomas	President & CEO	Nov 13 '25	Buy	32.11	30	963	39,007	Nov 14 09:15 AM
Snyder Mark S	VP- Engineering	Oct 16 '25	Buy	28.83	11	325	4,487	Oct 20 10:43 AM
Scarpato Matthew J	Chief Operating Officer	Oct 16 '25	Buy	28.83	34	975	866	Oct 20 10:36 AM
Poff Matthew E	Chief Financial Officer	Oct 16 '25	Buy	28.83	5	130	8,147	Oct 20 10:29 AM
Hand Joseph Thomas	President & CEO	Oct 16 '25	Buy	28.83	338	9,750	38,977	Oct 20 10:09 AM
Grimm Ashley M	VP- Human Resources	Oct 16 '25	Buy	28.83	14	390	317	Oct 20 10:00 AM
Hand Joseph Thomas	President & CEO	Oct 03 '25	Buy	30.07	15	451	38,352	Oct 06 09:28 AM
Hand Joseph Thomas	President & CEO	Sep 09 '25	Buy	30.68	200	6,136	38,337	Sep 09 05:36 PM
Snyder Mark S	VP- Engineering	Jul 16 '25	Buy	29.89	11	325	4,442	Jul 17 10:43 AM
Scarpato Matthew J	VP- Operations	Jul 16 '25	Buy	29.89	33	975	826	Jul 17 10:29 AM
Poff Matthew E	Chief Financial Officer	Jul 16 '25	Buy	29.89	4	130	8,082	Jul 17 09:48 AM
Hand Joseph Thomas	CEO & President	Jul 16 '25	Buy	29.89	326	9,750	38,137	Jul 17 09:41 AM
Grimm Ashley M	VP- Human Resources	Jul 16 '25	Buy	29.89	13	390	303	Jul 17 09:34 AM
Chiaruttini Alexandra C	CAO & General Counsel	Jul 16 '25	Buy	29.89	43	1,300	4,717	Jul 17 09:20 AM
Hand Joseph Thomas	CEO & President	Jun 18 '25	Buy	32.07	25	802	37,541	Jun 20 09:25 AM
Chiaruttini Alexandra C	CAO & General Counsel	Apr 16 '25	Buy	33.11	39	1,300	3,588	Apr 16 02:43 PM
Grimm Ashley M	VP- Human Resources	Apr 16 '25	Buy	33.11	12	390	34	Apr 16 02:21 PM
Hand Joseph Thomas	CEO & President	Apr 16 '25	Buy	33.11	294	9,750	35,813	Apr 16 02:13 PM
Poff Matthew E	Chief Financial Officer	Apr 16 '25	Buy	33.11	4	130	6,860	Apr 16 01:59 PM
Scarpato Matthew J	VP- Operations	Apr 16 '25	Buy	33.11	29	975	427	Apr 16 01:53 PM
Snyder Mark S	VP- Engineering	Apr 16 '25	Buy	33.11	10	325	4,035	Apr 16 01:43 PM
Hand Joseph Thomas	CEO & President	Mar 28 '25	Buy	34.66	20	693	35,273	Mar 31 08:22 AM
Lambert Robert F	Director	Feb 20 '25	Buy	32.73	15	500	15	Feb 20 04:00 PM

DLPN Dolphin Entertainment Inc daily Stock Chart

Peers: DIS NFLX CMCSA ROKU FOXA LGF-A PARA AMCX SONO TMUS

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	23.47%	Shs Outstand	11.98M	Perf Week	-6.02%
Market Cap	18.91M	Forward P/E	8.67	EPS next Y	0.18	Insider Trans	6.51%	Shs Float	9.28M	Perf Month	6.85%
Enterprise Value	39.44M	PEG	-	EPS next Q	0.00	Inst Own	2.97%	Short Float	0.22%	Perf Quarter	4.70%
Income	-6.07M	P/S	0.35	EPS this Y	70.49%	Inst Trans	-6.09%	Short Ratio	0.51	Perf Half Y	19.08%
Sales	53.37M	P/B	2.22	EPS next Y	150.00%	ROA	-10.35%	Short Interest	0.02M	Perf YTD	0.00%
Book/sh	0.70	P/C	2.16	EPS next 5Y	-	ROE	-55.09%	52W High	1.88 -17.02%	Perf Year	49.63%
Cash/sh	0.72	P/FCF	-	EPS past 3/5Y	10.35% 13.82%	ROIC	-20.46%	52W Low	0.75 108.84%	Perf 3Y	-66.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.10% 15.63%	Gross Margin	14.94%	Volatility	4.16% 5.20%	Perf 5Y	-80.84%
Dividend TTM	-	EV/Sales	0.74	EPS Y/Y TTM	81.68%	Oper. Margin	-4.76%	ATR (14)	0.08	Perf 10Y	-97.56%
Dividend Ex-Date	-	Quick Ratio	0.82	Sales Y/Y TTM	3.86%	Profit Margin	-11.37%	RSI (14)	47.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.82	EPS Q/Q	98.05%	SMA20	0.39%	Beta	2.60	Target Price	5.00
Payout	-	Debt/Eq	3.47	Sales Q/Q	16.67%	SMA50	-2.09%	Rel Volume	1.08	Prev Close	1.56
Employees	269	LT Debt/Eq	2.52	Earnings	Nov 12 AMC	SMA200	18.77%	Avg Volume	41.06K	Price	1.56
IPO	Oct 12, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	50.00% 5.69%	Trades		Volume	44,000	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-02-21	Reiterated	Maxim Group	Buy	$28
Jan-03-19	Resumed	Maxim Group	Buy	$4.50

Jan-20-26 09:00AM	Dolphin Subsidiary 42West Brings Exciting and Diverse Projects to the 2026 Sundance Film Festival (ACCESSWIRE)
Jan-13-26 09:00AM	Official Trailer and Key Art Released for Hubert Davis' Adaptation of Hockey Classic "Youngblood" (ACCESSWIRE)
Jan-06-26 09:00AM	Dolphin CEO Issues Letter to Shareholders: Highlights Organic Growth, Financial Strength, AI Leadership, Insider Buying and Positive 2026 Outlook (ACCESSWIRE)
Jan-02-26 09:37AM	Actions Speak Louder: Why This CEO Kept Buying His Own Stock (MarketBeat)
Dec-30-25 09:00AM	Dolphin Subsidiary The Door Provides Strategic Communications Leadership for Hooters as the Iconic Brand Enters a New Era of Ownership and Cultural Relevance (ACCESSWIRE) +11.36%
09:00AM	Loading…
Dec-23-25 09:00AM	Dolphin Subsidiary Shore Fire Media's Podcast Clients Recognized as 2025's Best (ACCESSWIRE)
Dec-16-25 09:00AM	Dolphin Unveils New 'Dolphin Intelligence' Division to Power AI-Driven Marketing and Communications Strategy and Execution for Partners (ACCESSWIRE)
Dec-10-25 09:00AM	Dolphin Subsidiary 42West Lands Four Nominations for Clients at the 83rd Golden Globe Awards (ACCESSWIRE)
Dec-04-25 09:00AM	Dolphin Partners with Well Go USA for U.S. Distribution of YOUNGBLOOD (ACCESSWIRE)
Nov-19-25 09:00AM	Elle Communications is Agency of Record for FDA-Cleared Neurostimulation Device (ACCESSWIRE)
Nov-13-25 12:01AM	Dolphin Entertainment Inc (DLPN) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-12-25 04:10PM	Dolphin Announces Record Q3 Revenue of $14.8 Million, up 16.7% YoY (ACCESSWIRE)
09:00AM	Dolphin Clients Earn 35 Nominations for the 2026 GRAMMY Awards (ACCESSWIRE)
Nov-11-25 07:37AM	Dolphin Entertainment Inc (DLPN) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-07-25 09:25AM	Dolphin to Host Third Quarter 2025 Earnings Call on November 12 at 4:30 PM ET (ACCESSWIRE) -7.37%
09:00AM	Loading…
Nov-05-25 09:00AM	Dolphin Subsidiary Elle Communications Launches "The Shift," a Quarterly Report, Weekly Newsletter, and Live Workshop Series on the Future of Communications (ACCESSWIRE)
Oct-28-25 09:00AM	Dolphin (NASDAQ:DLPN) Named One of Crain's Best Places to Work in NYC 2025 (ACCESSWIRE)
Oct-22-25 09:00AM	Dolphin Subsidiary Special Projects Has Another Successful Year Of Talent Relations For The Academy Museum Of Motion Pictures Fifth Annual Gala Honoring Penelope Cruz, Walter Salles, Bruce Springsteen, And Bowen Yang (ACCESSWIRE) -5.13%
Oct-15-25 09:00AM	Dolphin Subsidiary Elle Communications Leads Press For "A Day Of Unreasonable Conversation" Summit At The Getty Center (ACCESSWIRE) -5.03%
Oct-08-25 09:00AM	Dolphin CEO Bill O'Dowd Named to PRNEWS 2025 People of the Year List; Company Recognized on Agency Elite 120 (ACCESSWIRE)
Sep-30-25 09:25AM	Los Angeles Kings Board Feature Film Youngblood (ACCESSWIRE)
Sep-23-25 09:00AM	42WEST, a Subsidiary of Dolphin, Drives Global Reveal of 30 Ninjas' Asteroid - Backed by Google's Android XR and CAA (ACCESSWIRE)
Sep-18-25 09:00AM	BRANDEdit Experience During Fashion Week, Largest To Date, Immerses Top Creators in the Future of Fashion, Beauty, and Wellness (ACCESSWIRE)
Sep-16-25 09:15AM	Dolphin Subsidiary 42West's Clients Score 5 Primetime Emmy Wins (ACCESSWIRE)
Sep-11-25 09:00AM	Dolphin Named to The PR Net 100 (ACCESSWIRE)
Sep-09-25 09:00AM	Dolphin Subsidiary Special Projects Remains a Driving Force at New York Fashion Week, Partnering with CHANEL, FENDI, J.Crew, W Magazine and NYLON (ACCESSWIRE)
Sep-02-25 09:00AM	Dolphin Subsidiary 42West Prepares for the Fall Festival Season with Prolific Client Slate (ACCESSWIRE)
Aug-26-25 09:00AM	Dolphin Subsidiary The Door Expands Hospitality Footprint as Jesse Gerstein Rejoins with Top Tier Hospitality Client Roster (ACCESSWIRE) +6.14%
Aug-21-25 09:00AM	Elle Communications Expands Literary Footprint, Driving Acclaimed Book Launches Across Social Justice, Memoir, and Cultural Commentary (ACCESSWIRE)
Aug-14-25 03:13AM	Dolphin Entertainment Inc (DLPN) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com) +7.69%
04:20PM	Loading…
Aug-13-25 04:20PM	Dolphin Announces Record Q2 Revenue of $14.1 Million, up 23% YoY; Deepens Investment in Women's Sports and Affiliate Marketing (ACCESSWIRE)
09:00AM	Dolphin Forms New Division to Elevate Culinary and Lifestyle Talent (ACCESSWIRE)
Aug-12-25 09:44AM	Earnings To Watch: Dolphin Entertainment Inc (DLPN) Reports Q2 2025 Result (GuruFocus.com)
09:17AM	Youngblood Feature Adaptation Selected to Premiere at the 2025 Toronto International Film Festival (ACCESSWIRE)
Aug-07-25 04:05PM	Dolphin to Host Second Quarter 2025 Earnings Call on August 13 at 4:30 PM ET (ACCESSWIRE)
Aug-05-25 09:00AM	Dolphin Subsidiary Special Projects Secures Talent Lineup For The Fifth Annual Academy Museum Gala (ACCESSWIRE) +5.45%
Jul-28-25 09:00AM	Dolphin Subsidiary 42West Dominates at San Diego Comic-Con (SDCC) 2025 (ACCESSWIRE)
Jul-22-25 09:00AM	Shore Fire Media Named PR Agency of Record for the Miles Davis Estate Ahead of 2026 Centennial (ACCESSWIRE) +9.17%
Jul-16-25 09:00AM	Dolphin Subsidiary 42West's Clients Earn 15 Primetime Emmy Nominations (ACCESSWIRE)
Jul-15-25 05:01PM	William O'Dowd Increases Stake in Dolphin Entertainment, Inc. (DLPN) (Insider Monkey)
Jul-09-25 09:00AM	Dolphin's Consortium of Best-in-Class PR and Marketing Agencies to Represent The Lumistella Company, Global Toy and Entertainment Brand (ACCESSWIRE)
Jul-01-25 09:00AM	DISRPT Agency, a Division of Dolphin Subsidiary The Door, Rolls Out 2025 Client Roster, Reinforcing Its Position at the Forefront of Cultural Influence (ACCESSWIRE)
Jun-24-25 09:25AM	Dolphin Subsidiaries and Clients Have Successful Showing at Cannes Lions Festival of Creativity 2025 (ACCESSWIRE) +5.45%
Jun-17-25 09:00AM	Dolphin Subsidiary 42West Makes Impact at 2025 Tribeca Festival with Exciting Film, TV, and Filmmaker Slate (ACCESSWIRE)
Jun-11-25 09:00AM	Dolphin Subsidiaries Shore Fire Media and The Digital Dept. Take Over CMA Fest 2025 (ACCESSWIRE)
Jun-03-25 09:00AM	Dolphin Subsidiary Special Projects Partners with The Peabody Awards on 2025 Awards Ceremony (ACCESSWIRE)
May-29-25 09:00AM	Dolphin to Present at Maxim Group's 2025 Virtual Tech Conference (ACCESSWIRE)
May-27-25 09:00AM	Shore Fire Media Clients Shape the Summer 2025 Season With Star-Studded Music Festivals and Concert Series (ACCESSWIRE)
May-20-25 09:00AM	Dolphin Subsidiary Special Projects Curates Star-Studded Guest List for the Tory Burch Store Opening on Rodeo Drive (ACCESSWIRE)
May-14-25 03:15AM	Dolphin Entertainment Inc (DLPN) Q1 2025 Earnings Call Highlights: Strategic Growth Amid ... (GuruFocus.com)
May-13-25 04:08PM	Dolphin Reports Q1 2025 Results; Core Entertainment Publicity and Marketing Segment (EPM) Revenue Up 2% YoY to $12.1 Million, Strategic Investments and New Division Launch to Drive Long-Term Growth (ACCESSWIRE)
09:00AM	Dolphin Subsidiary The Digital Dept. Sees Surge In Affiliate Marketing Division, Driving Over $6.6 Million In Gross Retail Sales In First Quarter (ACCESSWIRE)
May-08-25 04:01PM	Dolphin to Host First Quarter 2025 Earnings Call on May 13 at 4:30 PM ET (ACCESSWIRE)
May-07-25 09:00AM	Dolphin Clients Shine at the 2025 Met Gala (ACCESSWIRE)
Apr-29-25 09:00AM	Longtime Shore Fire Media Client Cyndi Lauper To Be Inducted Into Rock & Roll Hall of Fame (ACCESSWIRE)
Apr-22-25 09:00AM	Dolphin Subsidiary the Digital Dept. Hosts Highest-Grossing BRANDEdit Influencer Experience to Date in Los Angeles (ACCESSWIRE)
Apr-15-25 09:00AM	Dolphin CEO Bill O'Dowd Featured on CEO.com Podcast: from Bedroom Startup to Media Powerhouse (ACCESSWIRE)
Apr-10-25 09:00AM	Dolphin Subsidiary Special Projects Springs into the New Season, Partnering with MAX, Warner Bros. and Louis Vuitton (ACCESSWIRE)
Apr-08-25 09:00AM	Dolphin to Present at the LD Micro Investor Conference in New York City on April 10, 2025 at 2:00pm ET (ACCESSWIRE)
Apr-03-25 09:00AM	Dolphin CEO Bill O'Dowd Starts $250,000 10b5-1 Stock Purchase Plan This Week, Building on $100,000 Purchase in 2H 2024; Bullish on Dolphin's Undervalued Shares and Future Growth (ACCESSWIRE)
Mar-28-25 03:21PM	Dolphin Entertainment, Inc. (DLPN) Q4 2024 Earnings Call Transcript (Seeking Alpha)
03:04AM	Dolphin Entertainment Inc (DLPN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Mar-27-25 04:13PM	Dolphin Reports 20% Year-Over-Year Revenue Growth to $51.7 Million and Full-Year Positive Adjusted Operating Income for Fiscal Year 2024 (ACCESSWIRE)
01:20PM	Dolphin Partner Loti AI Expands Digital Identity Protection To Everyone (ACCESSWIRE)
Mar-26-25 09:00AM	Dolphin to Host Fourth Quarter and FY 2023 Earnings Call on March 27 at 4:30 PM ET (ACCESSWIRE)
Mar-18-25 12:00PM	Dolphin Agencies Showcase Key Clients and Projects at 2025 SXSW Festival (ACCESSWIRE)
Mar-11-25 09:00AM	Dolphin to Participate at the 37th Annual ROTH Conference in Dana Point, CA on March 18, 2025 (ACCESSWIRE) +6.93%
Mar-06-25 09:00AM	DOLPHIN Along With Subsidiary ALWAYS ALPHA to Ring the NASDAQ Closing Bell on March 7 to Celebrate Women in Sports and International Women's Day (ACCESSWIRE)
Mar-05-25 09:00AM	42West Shines at Toy Fair Representing Funko, the Op Games and Super7 (ACCESSWIRE)
Mar-04-25 09:00AM	42West and Shore Fire Clients Shine During Oscars Week (ACCESSWIRE)
Feb-27-25 09:00AM	'The Blue Angels' Wins for Outstanding Achievement in Sound Editing for a Feature Documentary at the MPSE Golden Reel Awards (ACCESSWIRE) -5.11%
Feb-26-25 09:41AM	Dolphins The Door announces roster of chef, lifestyle talent (TipRanks)
Feb-25-25 09:00AM	Dolphin Subsidiary the Door Announces Major Roster of Chef and Lifestyle Talent for 2025 Showcasing Its Prowess for Culinary Launches and Brand Expansion (ACCESS Newswire)
Feb-19-25 09:00AM	Dolphin Expands Loyalty Program With Exclusive New Perks (ACCESSWIRE)
Feb-12-25 09:00AM	Dolphin Leads Major Brand Activations During Super Bowl LVIII (ACCESSWIRE) +5.77%
09:00AM	Dolphin Leads Major Brand Activations During Super Bowl LIX (ACCESS Newswire)
Feb-10-25 09:00AM	Youngblood Feature Adaptation Begins Principal Photography (ACCESSWIRE)
Feb-05-25 08:00AM	Deep Blue Sports + Entertainment Announces Joint Venture With Always Alpha, Creating Women's Sports' First Full-Service Management Offering (ACCESSWIRE)
Feb-04-25 11:00AM	Dolphin Companies Shore Fire Media and 42West's Clients Earn 10 Wins at the 2025 Grammy Awards (ACCESSWIRE)
Feb-03-25 09:00AM	Dolphin (Nasdaq:DLPN) Named Agency of the Year on the 2025 Observer PR Power List (ACCESSWIRE)
Jan-28-25 09:00AM	Dolphin Subsidiary the Digital Dept. Launches New Division for Affiliate Marketing and Content Creator Services (ACCESSWIRE)
Jan-24-25 09:00AM	Dolphin Subsidiary 42West Lands Eight Nominations for Clients at the 97th Academy Awards (ACCESSWIRE)
Jan-22-25 09:00AM	Dolphin Subsidiary 42West Supports Exciting New Projects at the 2025 Sundance Film Festival (ACCESSWIRE)
Jan-16-25 09:00AM	Documentary Sensation 'The Blue Angels' Soars Back Into Select Imax(R) Theatres as a New Version Offered in Breathtaking New Imax 3D Presentations Across the Globe Starting January 17th (ACCESSWIRE)
Jan-14-25 09:00AM	Dolphin (NASDAQ:DLPN) Launches "The Pod" Shareholder Loyalty Program Through New Partnership with TiiCKER (ACCESSWIRE)
Jan-07-25 09:00AM	Dolphin Subsidiary, Influencer Marketing Powerhouse, the Digital Dept., Expands BRANDEdit Experiences and Corporate Event Services for 2025 (ACCESSWIRE)
Dec-23-24 09:00AM	Shore Fire Media Client Bonnie Raitt and 42West Client Francis Ford Coppola are Recognized at the Kennedy Center Honors (ACCESSWIRE) -11.42%
Dec-17-24 09:00AM	Dolphin Set to Launch Shareholder Loyalty Program to Engage and Reward Retail Investors (ACCESSWIRE) +5.56%
Dec-10-24 09:15AM	Dolphin Entertainment Embarks on an Inspiring Journey to Adapt Clare Mulley's Award-Winning Debut Biography the Woman Who Saved the Children Into a Feature Film (ACCESSWIRE)
Nov-21-24 09:00AM	Dolphin-Owned Elle Communications Client Roster Recognized by Anthem Awards for Outstanding Social Impact (ACCESSWIRE) -5.26%
Nov-19-24 09:00AM	Culinary Icon Rachael Ray's Staple Gin Partners with FreshDirect to Offer Exclusive Holiday Recipes (ACCESSWIRE) +6.42%
Nov-15-24 02:15AM	Dolphin Entertainment Inc (DLPN) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst ... (GuruFocus.com) -5.98%
Nov-14-24 04:01PM	Dolphin Q3 Revenue Increases 24.5% YoY to $12.7M, Reports Adjusted Operating Income of $0.5M and Highlights Market Valuation Disconnect (ACCESSWIRE)
04:00AM	Dolphin Entertainment Regains Compliance With NASDAQ $1.00 Minimum Bid Price Listing Requirement (ACCESSWIRE)
Nov-13-24 07:34AM	Earnings To Watch: Dolphin Entertainment Inc (DLPN) Reports Q3 2024 Result (GuruFocus.com)
Nov-12-24 09:00AM	Dolphin Subsidiary Shore Fire Media Clients Earn 26 Nominations for the 2025 GRAMMY Awards, Including Album of the Year (ACCESSWIRE)
Nov-11-24 09:00AM	Dolphin to Host Third Quarter 2024 Earnings Call on November 14, 2024, at 4:30 PM ET (ACCESSWIRE)
Nov-07-24 09:00AM	Special Projects, Dolphin's Talent Booking Powerhouse, Curates Star-Studded Lineup for WSJ. Magazine's Innovator Awards at Moma for Ninth Year (ACCESSWIRE)
Oct-29-24 09:39AM	Dolphin Partners With Loti AI to Protect Brands, Talent and Clients From Online Deepfakes & More (ACCESSWIRE)
Oct-23-24 09:00AM	Dolphin Subsidiary Special Projects Contributes to the Success of the Academy Museum of Motion Pictures Fourth Annual Gala Honoring Paul Mescal, Rita Moreno, and Quentin Tarantino, Raising Over $11 Million (ACCESSWIRE)

Dolphin Entertainment, Inc. engages in the provision of entertainment marketing and content development. It operates through the following segments: Entertainment Publicity and Marketing, and Content Production. The Entertainment Publicity and Marketing segment consists of 42West, The Door, Viewpoint, and Shore Fire Media. The Content Production segment consists of Dolphin Entertainment and Dolphin Films. The company was founded on March 7, 1995 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Dowd William IV	Chief Executive Officer	Jan 20 '26	Buy	1.61	3,100	4,988	426,090	Jan 20 04:00 PM
O'Dowd William IV	Chief Executive Officer	Jan 12 '26	Buy	1.66	3,000	4,980	422,990	Jan 13 04:57 PM
O'Dowd William IV	Chief Executive Officer	Jan 05 '26	Buy	1.62	3,000	4,866	419,990	Jan 05 05:06 PM
O'Dowd William IV	Chief Executive Officer	Dec 29 '25	Buy	1.38	3,600	4,957	416,990	Dec 29 08:36 PM
O'Dowd William IV	Chief Executive Officer	Dec 22 '25	Buy	1.50	3,300	4,957	413,390	Dec 23 04:37 PM
O'Dowd William IV	Chief Executive Officer	Dec 19 '25	Buy	1.54	4,452	6,856	410,090	Dec 22 04:13 PM
O'Dowd William IV	Chief Executive Officer	Dec 15 '25	Buy	1.16	3,000	3,489	405,638	Dec 16 04:30 PM
O'Dowd William IV	Chief Executive Officer	Dec 08 '25	Buy	1.66	3,000	4,971	402,638	Dec 08 04:15 PM
O'Dowd William IV	Chief Executive Officer	Dec 01 '25	Buy	1.67	2,950	4,924	399,638	Dec 01 04:05 PM
O'Dowd William IV	Chief Executive Officer	Nov 10 '25	Buy	1.59	3,100	4,917	396,688	Nov 10 05:05 PM
O'Dowd William IV	Chief Executive Officer	Nov 03 '25	Buy	1.78	2,800	4,973	393,588	Nov 04 04:41 PM
O'Dowd William IV	Chief Executive Officer	Oct 27 '25	Buy	1.64	3,000	4,920	390,788	Oct 28 06:18 PM
O'Dowd William IV	Chief Executive Officer	Oct 20 '25	Buy	1.48	3,300	4,884	387,788	Oct 20 06:03 PM
O'Dowd William IV	Chief Executive Officer	Oct 13 '25	Buy	1.44	3,400	4,896	384,488	Oct 14 08:30 AM
O'Dowd William IV	Chief Executive Officer	Oct 06 '25	Buy	1.55	3,214	4,982	381,088	Oct 06 05:47 PM
O'Dowd William IV	Chief Executive Officer	Sep 29 '25	Buy	1.32	3,700	4,891	377,874	Sep 29 03:53 PM
O'Dowd William IV	Chief Executive Officer	Sep 22 '25	Buy	1.33	3,700	4,921	374,174	Sep 22 04:53 PM
O'Dowd William IV	Chief Executive Officer	Sep 15 '25	Buy	1.22	4,100	4,994	370,474	Sep 15 05:10 PM
O'Dowd William IV	Chief Executive Officer	Sep 08 '25	Buy	1.19	4,150	4,926	366,374	Sep 08 05:54 PM
O'Dowd William IV	Chief Executive Officer	Sep 02 '25	Buy	1.21	4,100	4,977	362,224	Sep 02 04:43 PM
O'Dowd William IV	Chief Executive Officer	Aug 25 '25	Buy	1.13	4,400	4,954	358,124	Aug 27 04:16 PM
O'Dowd William IV	Chief Executive Officer	Aug 21 '25	Buy	1.18	84,745	99,999	353,724	Aug 25 05:10 PM
O'Dowd William IV	Chief Executive Officer	Aug 18 '25	Buy	1.15	4,300	4,924	268,979	Aug 19 04:54 PM
O'Dowd William IV	Chief Executive Officer	Aug 11 '25	Buy	1.13	4,400	4,985	264,679	Aug 13 04:08 PM
O'Dowd William IV	Chief Executive Officer	Aug 04 '25	Buy	1.12	4,400	4,915	260,279	Aug 05 05:11 PM
O'Dowd William IV	Chief Executive Officer	Jul 28 '25	Buy	1.33	3,750	4,976	255,879	Jul 29 04:26 PM
O'Dowd William IV	Chief Executive Officer	Jul 21 '25	Buy	1.19	4,150	4,943	252,129	Jul 21 04:07 PM
O'Dowd William IV	Chief Executive Officer	Jul 14 '25	Buy	1.28	3,900	4,984	247,979	Jul 15 11:32 AM
O'Dowd William IV	Chief Executive Officer	Jul 07 '25	Buy	1.34	3,700	4,962	244,079	Jul 07 04:01 PM
O'Dowd William IV	Chief Executive Officer	Jun 30 '25	Buy	1.13	4,400	4,981	240,379	Jun 30 06:44 PM
O'Dowd William IV	Chief Executive Officer	Jun 25 '25	Buy	1.20	4,150	4,976	235,979	Jun 25 05:10 PM
O'Dowd William IV	Chief Executive Officer	Jun 23 '25	Buy	1.14	4,350	4,946	231,829	Jun 23 08:57 PM
O'Dowd William IV	Chief Executive Officer	Jun 18 '25	Buy	1.14	4,350	4,955	227,479	Jun 18 12:37 PM
O'Dowd William IV	Chief Executive Officer	Jun 16 '25	Buy	1.15	4,300	4,958	223,129	Jun 16 04:13 PM
O'Dowd William IV	Chief Executive Officer	Jun 11 '25	Buy	1.20	4,150	4,968	218,829	Jun 11 04:32 PM
O'Dowd William IV	Chief Executive Officer	Jun 09 '25	Buy	1.20	4,150	4,962	214,679	Jun 09 04:15 PM
O'Dowd William IV	Chief Executive Officer	Jun 04 '25	Buy	1.08	4,600	4,968	210,529	Jun 04 05:18 PM
O'Dowd William IV	Chief Executive Officer	Jun 02 '25	Buy	1.06	4,700	4,982	205,929	Jun 02 05:30 PM
O'Dowd William IV	Chief Executive Officer	May 28 '25	Buy	1.10	4,500	4,950	201,229	May 29 03:51 PM
O'Dowd William IV	Chief Executive Officer	May 27 '25	Buy	1.09	4,590	5,003	196,729	May 27 08:57 PM
O'Dowd William IV	Chief Executive Officer	May 21 '25	Buy	1.15	4,300	4,945	192,139	May 21 02:05 PM
O'Dowd William IV	Chief Executive Officer	May 19 '25	Buy	1.12	4,368	4,892	187,839	May 20 09:49 PM
O'Dowd William IV	Chief Executive Officer	May 12 '25	Buy	1.05	4,600	4,830	183,471	May 13 04:29 PM
O'Dowd William IV	Chief Executive Officer	May 05 '25	Buy	1.12	4,400	4,928	178,871	May 05 07:48 PM
O'Dowd William IV	Chief Executive Officer	Apr 28 '25	Buy	1.10	4,508	4,959	174,471	Apr 30 05:42 PM
O'Dowd William IV	Chief Executive Officer	Apr 21 '25	Buy	1.02	4,900	4,988	167,213	Apr 21 04:53 PM
O'Dowd William IV	Chief Executive Officer	Apr 14 '25	Buy	1.05	4,700	4,935	162,313	Apr 14 04:26 PM
O'Dowd William IV	Chief Executive Officer	Apr 07 '25	Buy	0.96	5,200	4,982	157,613	Apr 07 07:10 PM
O'Dowd William IV	Chief Executive Officer	Apr 01 '25	Buy	1.01	4,920	4,969	152,413	Apr 01 05:49 PM

Open in Screener

NEOG

Neogen Corp

Jan 21 • 04:00PM ET

9.87

+0.52 5.56 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: TMO STE WAT CTLT BIO AVTR TECH ICUI BRKR STAA

| Held by: IJR IWM VTI VB VBR IJS SPSM IWN VXF SLYV

Index	RUT	P/E	-	EPS (ttm)	-2.78	Insider Own	0.81%	Shs Outstand	217.53M	Perf Week	7.40%
Market Cap	2.15B	Forward P/E	29.66	EPS next Y	0.33	Insider Trans	0.02%	Shs Float	215.76M	Perf Month	32.13%
Enterprise Value	2.79B	PEG	-	EPS next Q	0.06	Inst Own	112.54%	Short Float	7.93%	Perf Quarter	67.57%
Income	-602.74M	P/S	2.44	EPS this Y	106.84%	Inst Trans	-4.41%	Short Ratio	4.42	Perf Half Y	96.61%
Sales	880.32M	P/B	1.02	EPS next Y	-3.27%	ROA	-16.26%	Short Interest	17.11M	Perf YTD	41.20%
Book/sh	9.67	P/C	14.77	EPS next 5Y	-	ROE	-25.25%	52W High	12.07 -18.23%	Perf Year	-14.62%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	- -	ROIC	-20.80%	52W Low	3.87 155.03%	Perf 3Y	-44.74%
Dividend Est.	-	EV/EBITDA	26.27	Sales past 3/5Y	19.28% 16.43%	Gross Margin	35.45%	Volatility	5.43% 5.27%	Perf 5Y	-76.21%
Dividend TTM	-	EV/Sales	3.17	EPS Y/Y TTM	-26.40%	Oper. Margin	-1.27%	ATR (14)	0.53	Perf 10Y	-50.86%
Dividend Ex-Date	-	Quick Ratio	2.80	Sales Y/Y TTM	-3.67%	Profit Margin	-68.47%	RSI (14)	76.53	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	3.91	EPS Q/Q	96.52%	SMA20	20.31%	Beta	1.94	Target Price	11.00
Payout	-	Debt/Eq	0.38	Sales Q/Q	-2.84%	SMA50	39.34%	Rel Volume	0.67	Prev Close	9.35
Employees	2974	LT Debt/Eq	0.38	Earnings	Jan 08 BMO	SMA200	66.00%	Avg Volume	3.87M	Price	9.87
IPO	Aug 23, 1989	Option/Short	Yes / Yes	EPS/Sales Surpr.	57.98% 8.18%	Trades		Volume	2,578,852	Change	5.56%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-25	Downgrade	William Blair	Outperform → Mkt Perform
Dec-19-24	Initiated	Guggenheim	Buy	$15
Jun-16-23	Initiated	Wells Fargo	Overweight	$22
Nov-22-22	Upgrade	William Blair	Mkt Perform → Outperform
Jul-12-22	Initiated	Piper Sandler	Neutral	$25
May-23-19	Initiated	Guggenheim	Neutral
Dec-05-17	Resumed	ROTH Capital	Neutral	$82
Jul-14-17	Initiated	CL King	Neutral
Jun-05-14	Initiated	William Blair	Mkt Perform
Mar-31-11	Upgrade	Hilliard Lyons	Underperform → Neutral
Sep-25-09	Reiterated	Roth Capital	Buy	$33 → $36
Jul-22-09	Reiterated	Roth Capital	Buy	$29 → $33
Mar-20-09	Reiterated	Roth Capital	Buy	$32 → $28
Jan-07-09	Reiterated	Roth Capital	Buy	$33 → $32
Sep-25-08	Reiterated	Roth Capital	Buy	$30 → $33
Jan-04-08	Reiterated	Roth Capital	Buy	$28 → $30
Sep-28-07	Reiterated	Roth Capital	Buy	$23.33 → $28
Jul-25-07	Reiterated	Roth Capital	Buy	$33 → $35
Jul-09-07	Reiterated	Roth Capital	Buy	$27 → $33
May-08-07	Initiated	Susquehanna Financial	Positive

Show Previous Ratings

Jan-15-26 12:31AM	5 Insightful Analyst Questions From Neogen's Q4 Earnings Call (StockStory)
Jan-12-26 07:45AM	Neogen's Q2 Earnings and Revenues Beat Estimates, Stock Climbs (Zacks)
Jan-09-26 09:49AM	Company News for Jan 9, 2026 (Zacks)
12:30AM	NEOG Q4 Deep Dive: Operational Improvements and New Leadership Drive Upbeat Outlook (StockStory)
Jan-08-26 10:30PM	Neogen (NEOG) Hits 10-Month High on Earnings, Upbeat Outlook (Insider Monkey) +31.57%
07:24PM	Loading…
07:24PM	Why Neogen Stock Blasted More Than 31% Higher Today (Motley Fool)
06:00PM	Compared to Estimates, Neogen (NEOG) Q2 Earnings: A Look at Key Metrics (Zacks)
04:53PM	These Stocks Moved the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More (Barrons.com)
03:29PM	These Stocks Are Moving the Most Today: Lockheed, Northrop, Alphabet, Applied Digital, Bloom Energy, Neogen, and More (Barrons.com)
02:25PM	Neogen Stock Spikes 32% After Earnings Beat and Raised Outlook (Barrons.com)
02:00PM	Neogen Corp (NEOG) Q2 2026 Earnings Call Highlights: Strong Core Growth and Improved Profitability (GuruFocus.com)
01:09PM	Neogen's Raised Outlook Fuels Turnaround Hopes, Stock Soars (Benzinga)
11:35AM	Why Is Neogen (NEOG) Stock Rocketing Higher Today (StockStory)
10:44AM	Neogen Soars After Earnings Beat and Raised Outlook (Barrons.com)
07:30AM	Neogen Posts Narrower Loss In Q2 (RTT News)
07:15AM	Loading…
07:15AM	Neogen (NASDAQ:NEOG) Beats Expectations in Strong Q4 CY2025, Stock Jumps 19.8% (StockStory)
07:09AM	Neogen: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Neogen Announces Second-Quarter 2026 Results (Business Wire)
05:45AM	Earnings to put Commercial Metals' recent share price surge to the test (MarketWatch)
05:12AM	Stock Market Today: Dow, S&P 500 and Nasdaq point to lower open; Nvidia in focus on China chip sales hope; precious metals retreat (MarketWatch)
Jan-06-26 10:02PM	Neogen (NEOG) Q4 Earnings Report Preview: What To Look For (StockStory)
Jan-05-26 08:45AM	Neogen Announces Two Senior Leadership Appointments (Business Wire)
Jan-04-26 11:40PM	1 Healthcare Stock on Our Watchlist and 2 We Ignore (StockStory)
Dec-19-25 09:30AM	Oncobiologics, Inc. (OTLK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Dec-18-25 11:02PM	3 Reasons to Sell NEOG and 1 Stock to Buy Instead (StockStory) +5.36%
09:00AM	Neogen Announces Second-Quarter Earnings Release Date (Business Wire)
Dec-17-25 04:15PM	Neogen To Participate in Upcoming Investor Conferences (Business Wire)
Dec-16-25 11:26AM	Investors who lost money with shares of Neogen Corporation (NASDAQ: NEOG) should contact the Shareholders Foundation in connection with Lawsuit (PR Newswire)
Dec-10-25 08:34AM	Is it Worth Retaining NEOG Stock in Your Portfolio for Now? (Zacks) +9.06%
Dec-04-25 12:46PM	Neogen Corporation (NEOG): A Bull Case Theory (Insider Monkey)
11:37PM	Loading…
Dec-03-25 11:37PM	3 Unprofitable Stocks with Questionable Fundamentals (StockStory)
Nov-14-25 11:30AM	Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report? (Zacks)
Nov-04-25 10:34PM	Neogen (NASDAQ:NEOG) Q3 Earnings: Leading The Medical Devices & Supplies - Diversified Pack (StockStory)
08:01PM	Neogen Corp (NEOG) Q1 2026 Earnings Call Highlights: Strategic Cost Reductions and Innovation ... (GuruFocus.com)
09:55AM	Wall Street Analysts See a 29.89% Upside in Neogen (NEOG): Can the Stock Really Move This High? (Zacks)
Oct-30-25 08:45AM	Neogen Corporation Announces Appointment of Bryan Riggsbee as Chief Financial Officer (Business Wire)
Oct-16-25 01:31AM	5 Revealing Analyst Questions From Neogen's Q3 Earnings Call (StockStory)
Oct-10-25 08:39AM	Neogen Q1 Earnings Miss Estimates, Revenues Beat, Stock Climbs (Zacks) -10.91%
01:30AM	NEOG Q3 Deep Dive: Q3 Results, Guidance Reaffirmed, and Operational Turnaround in Focus (StockStory)
Oct-09-25 05:00PM	Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics (Zacks) +16.49%
12:05PM	Why Neogen (NEOG) Stock Is Trading Up Today (StockStory)
08:15AM	Neogen (NEOG) Q1 Earnings Lag Estimates (Zacks)
07:44AM	Neogen Stock Spikes After Earnings. Cost Cuts Will Include Layoffs. (Barrons.com)
07:25AM	Neogen (NASDAQ:NEOG) Exceeds Q3 Expectations, Stock Soars (StockStory)
07:10AM	Neogen: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Neogen Announces First-Quarter 2026 Results (Business Wire)
05:23AM	Delta, PepsiCo and Levi Strauss among the earnings due on Thursday (MarketWatch)
04:30AM	Stock Market Today: S&P 500 and Nasdaq hold record highs, Dow a fraction off its peak, as gold dips; Powell to speak. (MarketWatch)
Oct-07-25 11:00PM	Neogen (NEOG) Q3 Earnings Report Preview: What To Look For (StockStory)
Oct-06-25 09:15AM	Wall Street's Insights Into Key Metrics Ahead of Neogen (NEOG) Q1 Earnings (Zacks) -7.10%
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch)
10:00AM	Analysts Estimate Neogen (NEOG) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-01-25 12:03AM	Neogen (NEOG): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Sep-30-25 12:51PM	Neogen (NEOG) Stock Trades Up, Here Is Why (StockStory)
Sep-25-25 05:26PM	Neogen Renews Official Sponsorship with US Equestrian to Continue Advancing Equine Health Education (Business Wire) +5.78%
Sep-24-25 09:06AM	Neogen Corporation (NEOG) Slid Due to Below-Expected Revenue and Profitability (Insider Monkey)
Sep-18-25 04:15PM	Neogen Announces First-Quarter Earnings Release Date (Business Wire)
Sep-17-25 09:00AM	Stocks making big moves yesterday: Neogen, Rocket Lab, Hain Celestial, Chewy, and Oscar Health (StockStory)
Sep-16-25 11:40AM	Why Neogen (NEOG) Stock Is Down Today (StockStory)
Sep-15-25 04:01PM	Neogen Announces CFO Transition Plan (Business Wire)
Sep-11-25 03:55PM	Investors in Neogen Corporation (NEOG): Protect Your Rights - Contact Levi & Korsinsky Before September 16, 2025 (Newsfile)
Sep-03-25 05:02PM	Investors in Neogen Corporation (NEOG): Protect Your Rights - Contact Levi & Korsinsky Before September 16, 2025 (Newsfile)
Aug-27-25 10:00AM	Neogen Corporation (NEOG): A Bull Case Theory (Insider Monkey)
Aug-25-25 09:17AM	Investors Urged to Contact Levi & Korsinsky for Information Before September 16, 2025 - Neogen Corporation (NEOG) (Newsfile)
Aug-19-25 08:45AM	Shareholders of Neogen Corporation Should Contact Levi & Korsinsky Before September 16, 2025 to Discuss Your Rights - NEOG (PR Newswire)
Aug-17-25 06:06PM	Neogen Corp (NEOG) Beats Expectations Amid Leadership Change and Restructuring Efforts (Insider Monkey)
Aug-15-25 09:15AM	Neogen Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 16, 2025 to Discuss Your Rights - NEOG (PR Newswire)
Aug-14-25 04:15PM	Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm (Business Wire)
Aug-13-25 03:00PM	Why Neogen (NEOG) Stock Is Up Today (StockStory) +5.93%
12:09AM	The 5 Most Interesting Analyst Questions From Neogen's Q2 Earnings Call (StockStory)
Aug-12-25 11:51PM	NEOG Q2 Deep Dive: Market Pressures Persist, Regulatory Tailwinds and CEO Transition Shape Outlook (StockStory)
09:00AM	Investors in Neogen Corporation Should Contact Levi & Korsinsky Before September 16, 2025 to Discuss Your Rights - NEOG (PR Newswire)
Aug-11-25 08:45AM	Neogen Establishes Relationship with Biomatter (Business Wire)
07:43AM	Does Neogen Corporation (NEOG) Have a Significant Upside? (Insider Monkey)
12:34AM	3 Small-Cap Stocks with Warning Signs (StockStory)
Aug-06-25 02:20PM	[Latest] Global Arabinogalactan Market Size/Share Worth USD 312 Million by 2034 at a 4.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) (GlobeNewswire)
Aug-04-25 11:31PM	Q2 Earnings Highlights: Neogen (NASDAQ:NEOG) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks (StockStory)
Aug-01-25 09:00AM	Neogen Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 16, 2025 to Discuss Your Rights - NEOG (PR Newswire)
Jul-30-25 05:00PM	Neogen (NEOG) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
03:04AM	Neogen Corp (NEOG) Q4 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
Jul-29-25 02:25PM	Neogen (NEOG) Stock Trades Down, Here Is Why (StockStory) -10.89%
08:15AM	Neogen (NEOG) Q4 Earnings Lag Estimates (Zacks)
07:27AM	Neogen (NASDAQ:NEOG) Posts Better-Than-Expected Sales In Q2, Guides for Strong Full-Year Sales (StockStory)
07:19AM	Neogen: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Neogen Announces Fourth-Quarter 2025 Results (Business Wire)
Jul-28-25 08:45AM	Neogen Expands its Pathogen Portfolio and Environmental Monitoring Solutions with a New Rapid Test for Listeria (Business Wire)
07:21AM	Here's Why Conestoga Capital Advisors Sold Neogen Corp. (NEOG) (Insider Monkey)
Jul-27-25 11:02PM	Neogen (NEOG) Q2 Earnings Report Preview: What To Look For (StockStory)
Jul-24-25 02:21PM	Neogen (NEOG) Stock Is Up, What You Need To Know (StockStory)
09:00AM	Neogen Corporation Announces Appointment of Mike Nassif as CEO and President (Business Wire)
Jul-23-25 04:23PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 16, 2025 - Neogen Corporation (NEOG) (Newsfile)
10:00AM	InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-22-25 10:00AM	Earnings Preview: Neogen (NEOG) Q4 Earnings Expected to Decline (Zacks) +5.02%
Jul-18-25 08:45AM	Neogen Completes Sale of Cleaners & Disinfectants Business to Kersia Group (Business Wire)
Jul-15-25 04:03PM	Neogen (NEOG): A Bull Case Theory (Insider Monkey)
Jul-08-25 04:05PM	Neogen Announces Fourth-Quarter Earnings Release Date (Business Wire) +5.22%
Jun-05-25 08:30AM	Neogen Launches Second Edition Environmental Monitoring Handbook to Elevate Food Safety Practices (Business Wire)
Jun-04-25 01:27PM	Why Neogen (NEOG) Stock Is Down Today (StockStory) -17.33%
May-23-25 11:30AM	ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
May-21-25 09:00AM	Neogen to Participate in the 45th Annual William Blair Growth Stock Conference (Business Wire)

Neogen Corp. engages in the provision of development, manufacture, and marketing of food and animal safety products. It operates through the Food Safety and Animal Safety segments. The Food Safety segment consists of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens, drug residues, and levels of general sanitation. The Animal Safety segment includes a line of consumable products marketed to veterinarians and animal health product distributors. The company was founded on June 30, 1981 and is headquartered in Lansing, MI.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nassif Mikheal	CEO	Jan 16 '26	Buy	9.33	137	1,279	632	Jan 16 09:04 AM
Naemura David H.	Former CFO	Dec 01 '25	Option Exercise	5.98	12,912	77,214	93,936	Dec 02 11:45 AM
Nassif Mikheal	CEO	Nov 03 '25	Buy	6.25	177	1,106	495	Nov 07 12:20 PM
BOREL JAMES C	Director	Oct 27 '25	Option Exercise	6.19	1,777	11,000	96,347	Oct 29 10:13 AM
CAPELLO JEFFREY D	Director	Oct 27 '25	Option Exercise	6.19	1,777	11,000	32,502	Oct 29 10:08 AM
Green Ronald D	Director	Oct 27 '25	Option Exercise	6.19	1,777	11,000	18,654	Oct 29 10:06 AM
Gupta Aashima	Director	Oct 27 '25	Option Exercise	6.19	1,777	11,000	27,790	Oct 29 10:03 AM
RODRIGUEZ RAFAEL A	Director	Oct 27 '25	Option Exercise	6.19	1,777	11,000	20,821	Oct 28 03:51 PM
Tobin James P	Director	Oct 27 '25	Option Exercise	6.19	1,777	11,000	43,347	Oct 28 03:48 PM
Woteki Catherine E	Director	Oct 27 '25	Option Exercise	6.19	1,777	11,000	19,117	Oct 28 03:39 PM
Rocklin Amy M	Chief Legal Officer	Oct 27 '25	Option Exercise	6.19	9,474	58,644	59,325	Oct 28 01:57 PM
Naemura David H.	Chief Financial Officer	Oct 27 '25	Option Exercise	6.19	15,504	95,970	85,285	Oct 28 01:46 PM
Jones Douglas Edward	Former COO	Oct 27 '25	Option Exercise	6.19	15,504	95,970	104,362	Oct 28 01:36 PM
ADENT JOHN EDWARD	Former CEO	Oct 27 '25	Option Exercise	6.19	38,759	239,918	371,608	Oct 28 01:27 PM
BOEHM WILLIAM T	Director	Oct 27 '25	Option Exercise	6.07	3,553	21,567	47,913	Oct 28 01:12 PM
CAPELLO JEFFREY D	Director	Oct 27 '25	Option Exercise	6.19	2,025	12,535	30,725	Oct 28 09:52 AM
BOREL JAMES C	Director	Oct 27 '25	Option Exercise	6.19	2,025	12,535	94,570	Oct 28 09:38 AM
Rocklin Amy M	Chief Legal Officer	Oct 13 '25	Option Exercise	6.04	294	1,776	49,966	Oct 14 03:35 PM
Jones Douglas Edward	Former COO	Oct 13 '25	Option Exercise	6.04	783	4,729	89,241	Oct 14 03:24 PM
ADENT JOHN EDWARD	Former CEO	Oct 13 '25	Option Exercise	6.04	3,063	18,501	333,714	Oct 14 02:59 PM
Rocklin Amy M	Chief Legal Officer	Oct 07 '25	Option Exercise	5.36	9,036	48,433	53,206	Oct 09 08:33 PM
Jones Douglas Edward	Former COO	Oct 07 '25	Option Exercise	5.63	12,940	72,852	94,787	Oct 09 08:28 PM
ADENT JOHN EDWARD	Former CEO	Oct 07 '25	Option Exercise	5.63	32,936	185,430	339,948	Oct 09 08:21 PM
Woteki Catherine E	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	15,315	Oct 09 05:03 PM
Tobin James P	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	39,545	Oct 09 05:00 PM
RODRIGUEZ RAFAEL A	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	17,019	Oct 09 04:58 PM
Gupta Aashima	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	23,988	Oct 09 04:54 PM
Green Ronald D	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	14,852	Oct 09 04:51 PM
CAPELLO JEFFREY D	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	28,700	Oct 09 04:48 PM
BOREL JAMES C	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	92,545	Oct 09 04:44 PM
BOEHM WILLIAM T	Director	Oct 07 '25	Option Exercise	5.63	2,071	11,660	38,285	Oct 09 04:36 PM
ADENT JOHN EDWARD	CEO	Aug 18 '25	Option Exercise	5.43	35,736	194,046	307,012	Aug 20 02:49 PM
Jones Douglas Edward	Chief Operating Officer	Aug 18 '25	Option Exercise	5.43	14,294	77,616	86,007	Aug 20 02:39 PM
Naemura David H.	CFO	Aug 18 '25	Option Exercise	5.43	14,294	77,616	75,728	Aug 20 11:57 AM
Rocklin Amy M	Chief Legal Officer	Aug 18 '25	Option Exercise	5.43	10,324	56,059	47,175	Aug 20 10:28 AM
Moylan John Patrick	Chief Accounting Officer	Aug 18 '25	Option Exercise	5.43	1,985	10,779	14,940	Aug 20 10:23 AM
Gupta Aashima	Director	May 12 '25	Buy	6.25	16,000	99,987	21,917	May 12 02:30 PM
Moylan John Patrick	Chief Accounting Officer	May 01 '25	Option Exercise	5.15	4,558	23,474	14,558	May 02 01:48 PM
ADENT JOHN EDWARD	CEO	Apr 28 '25	Option Exercise	5.16	2,112	10,898	271,276	Apr 29 01:39 PM
Jones Douglas Edward	Chief Operating Officer	Apr 28 '25	Option Exercise	5.16	845	4,360	72,004	Apr 29 01:34 PM
Rocklin Amy M	Chief Legal Officer	Apr 28 '25	Option Exercise	5.16	564	2,910	36,851	Apr 29 01:29 PM
Woteki Catherine E	Director	Apr 25 '25	Buy	5.17	5,770	29,831	13,244	Apr 25 04:32 PM
BOREL JAMES C	Director	Apr 24 '25	Buy	4.99	30,000	149,700	90,474	Apr 25 02:45 PM
BOEHM WILLIAM T	Director	Apr 24 '25	Buy	5.24	5,000	26,175	36,214	Apr 24 03:34 PM
BOREL JAMES C	Director	Apr 24 '25	Buy	4.89	35,000	171,290	60,474	Apr 24 11:18 AM
Rocklin Amy M	Chief Legal Officer	Apr 23 '25	Buy	4.99	12,500	62,375	36,287	Apr 23 10:46 AM
CAPELLO JEFFREY D	Director	Apr 22 '25	Buy	4.84	20,712	100,217	26,629	Apr 22 03:37 PM
Tobin James P	Director	Apr 22 '25	Buy	4.73	10,000	47,268	37,474	Apr 22 11:46 AM
RODRIGUEZ RAFAEL A	Director	Apr 22 '25	Buy	4.59	7,474	34,306	14,948	Apr 22 11:43 AM
Moylan John Patrick	Chief Accounting Officer	Apr 10 '25	Buy	5.07	10,000	50,700	10,000	Apr 10 10:12 AM

Open in Screener

BCDA

BioCardia Inc

Jan 21 • 04:00PM ET

1.28

-0.02 -1.54 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP BLUE NTLA CLLS QURE EDIT SGMO FATE BOLD CLRB

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-1.73	Insider Own	54.91%	Shs Outstand	10.61M	Perf Week	-7.91%
Market Cap	13.59M	Forward P/E	-	EPS next Y	-0.82	Insider Trans	14.53%	Shs Float	4.78M	Perf Month	0.00%
Enterprise Value	8.94M	PEG	-	EPS next Q	-0.17	Inst Own	4.05%	Short Float	5.22%	Perf Quarter	-12.93%
Income	-8.54M	P/S	-	EPS this Y	58.62%	Inst Trans	6.85%	Short Ratio	2.69	Perf Half Y	-44.23%
Sales	0.00M	P/B	5.17	EPS next Y	31.67%	ROA	-137.58%	Short Interest	0.25M	Perf YTD	2.40%
Book/sh	0.25	P/C	2.57	EPS next 5Y	34.77%	ROE	-317.47%	52W High	3.20 -60.00%	Perf Year	-41.28%
Cash/sh	0.50	P/FCF	-	EPS past 3/5Y	36.28% 40.58%	ROIC	-300.92%	52W Low	1.00 28.00%	Perf 3Y	-96.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-61.48% -39.41%	Gross Margin	-	Volatility	5.74% 5.59%	Perf 5Y	-97.64%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	58.50%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-99.22%
Dividend Ex-Date	-	Quick Ratio	1.62	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	43.36	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.62	EPS Q/Q	61.55%	SMA20	-2.35%	Beta	0.60	Target Price	15.50
Payout	-	Debt/Eq	0.24	Sales Q/Q	-	SMA50	-4.17%	Rel Volume	0.78	Prev Close	1.30
Employees	20	LT Debt/Eq	0.08	Earnings	Nov 12 AMC	SMA200	-29.03%	Avg Volume	92.85K	Price	1.28
IPO	Nov 13, 1996	Option/Short	No / Yes	EPS/Sales Surpr.	-4.35% -	Trades		Volume	81,999	Change	-1.54%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Dec-16-25 08:00AM	BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA (GlobeNewswire)
Dec-03-25 08:00AM	BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno (GlobeNewswire)
Dec-01-25 08:30AM	BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress (GlobeNewswire)
Nov-24-25 08:15AM	BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality (GlobeNewswire)
Nov-12-25 04:40PM	BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
08:30AM	Loading…
Nov-10-25 08:30AM	BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Nov-05-25 07:29PM	BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 (GlobeNewswire)
Oct-30-25 08:00AM	BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Oct-02-25 08:00AM	BioCardia Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-22-25 08:00AM	BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Sep-18-25 09:15AM	BioCardia Announces Pricing of Up To $12 Million Public Offering (GlobeNewswire) -23.78%
07:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up (GlobeNewswire)
Sep-04-25 09:00AM	BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 (GlobeNewswire)
Aug-13-25 08:00AM	BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology (GlobeNewswire) +6.90%
Aug-11-25 09:15AM	BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.15%
03:18PM	Loading…
Aug-06-25 03:18PM	BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 (GlobeNewswire) -5.52%
Aug-04-25 06:00AM	BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter (GlobeNewswire) -7.98%
Jul-24-25 09:00AM	BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure (GlobeNewswire)
Jul-16-25 08:45AM	Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Jun-25-25 08:00AM	BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
06:52AM	Loading…
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)
May-21-24 05:00PM	BioCardia Announces Reverse Stock Split (GlobeNewswire) -23.82%
May-15-24 03:08AM	BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ... (GuruFocus.com)
May-14-24 08:56PM	BCDA Stock Earnings: BioCardia Reported Results for Q1 2024 (InvestorPlace)
04:02PM	BioCardia Reports First Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
May-09-24 07:00AM	BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024 (GlobeNewswire)
May-01-24 07:00AM	BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes (GlobeNewswire)
Apr-25-24 09:00AM	BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort (GlobeNewswire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey)
Apr-01-24 02:30PM	BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 05:58AM	Q4 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-27-24 08:53PM	BCDA Stock Earnings: BioCardia Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:00PM	BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results (GlobeNewswire)
Mar-20-24 07:00AM	BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024 (GlobeNewswire)
Mar-13-24 07:00AM	BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership (GlobeNewswire)
Mar-12-24 07:00AM	BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study (GlobeNewswire) -9.49%
Mar-04-24 09:27AM	BioCardia rejigs phase 3 heart failure data to find a path forward for cell therapy (FierceBiotech.com) -21.51%
08:00AM	BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure (GlobeNewswire)
Feb-08-24 07:00AM	BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA (GlobeNewswire) -10.34%
Jan-31-24 07:00AM	BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -5.66%
Jan-03-24 07:00AM	BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders (GlobeNewswire)
Dec-19-23 07:00AM	BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Dec-18-23 07:16AM	BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes (GlobeNewswire) +8.32%
Nov-29-23 07:00AM	BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval (GlobeNewswire)
Nov-16-23 12:56PM	BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules (GlobeNewswire) -15.27%
Nov-15-23 11:04AM	BioCardia (BCDA) Soars 168% on FDA Nod to Heart Failure Study (Zacks) -11.68%
Nov-14-23 07:15AM	BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +168.17%
Nov-09-23 12:48PM	BioCardia, Inc. (NASDAQ:BCDA) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.75%
06:59AM	Q3 2023 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-08-23 05:52PM	BioCardia Inc (BCDA) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com) +6.10%
05:50PM	BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:11PM	BioCardia Reports Third Quarter 2023 Business Highlights and Financial Results (GlobeNewswire)
Nov-01-23 05:04PM	BioCardia to Host Q3 2023 Corporate Update and Financial Results Conference Call on November 8, 2023 (GlobeNewswire)
Oct-12-23 11:08AM	BioCardia (BCDA) Up on Plans for Second Heart Failure Study (Zacks) -13.88%

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and Avance Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Jan 20 '26	Buy	1.32	600	792	268,566	Jan 21 05:03 PM
Altman Peter	President and CEO	Jan 21 '26	Buy	1.34	300	402	268,866	Jan 21 05:03 PM
Altman Peter	President and CEO	Dec 17 '25	Buy	1.30	900	1,170	267,966	Dec 17 06:32 PM
Altman Peter	President and CEO	Dec 16 '25	Buy	1.37	200	274	267,066	Dec 17 06:32 PM
STERTZER SIMON H	Director	Sep 19 '25	Buy	1.25	398,400	498,000	591,054	Sep 23 09:00 AM
Blank Andrew Scott	Director	Sep 19 '25	Buy	1.25	288,000	360,000	634,023	Sep 23 09:00 AM
Altman Peter	President and CEO	Sep 19 '25	Buy	1.25	48,000	60,000	216,762	Sep 23 09:00 AM
Altman Peter	President and CEO	Aug 22 '25	Buy	1.83	700	1,281	168,762	Aug 25 09:30 AM
Altman Peter	President and CEO	Aug 13 '25	Buy	1.83	100	183	168,062	Aug 13 06:59 PM
Altman Peter	President and CEO	Aug 12 '25	Buy	1.75	400	700	167,962	Aug 12 07:23 PM
Altman Peter	President and CEO	Aug 11 '25	Buy	1.76	1,700	2,989	167,562	Aug 11 07:21 PM
McClung David	Chief Financial Officer	Jun 30 '25	Buy	2.08	4,819	9,999	47,950	Jul 02 09:03 PM
Altman Peter	President and CEO	Jun 30 '25	Buy	2.08	24,096	49,999	165,862	Jul 02 09:02 PM
STERTZER SIMON H	Director	Jun 30 '25	Buy	2.08	72,289	150,000	192,654	Jul 02 09:02 PM
Blank Andrew Scott	Director	Jun 30 '25	Buy	2.08	72,289	150,000	346,023	Jul 02 09:01 PM
Altman Peter	President and CEO	May 30 '25	Buy	2.21	100	221	141,766	May 30 08:55 PM
Altman Peter	President and CEO	May 20 '25	Buy	2.08	1,600	3,328	140,966	May 22 06:45 PM
Altman Peter	President and CEO	May 22 '25	Buy	1.89	700	1,323	141,666	May 22 06:45 PM
Altman Peter	President and CEO	May 16 '25	Buy	2.43	300	730	139,366	May 16 05:31 PM
Altman Peter	President and CEO	May 14 '25	Buy	2.99	100	299	139,066	May 16 05:31 PM
KRASNO RICHARD M	Director	Apr 23 '25	Buy	1.91	13,123	24,999	16,268	Apr 28 06:46 PM
McClung David	Chief Financial Officer	Apr 23 '25	Buy	1.91	13,123	24,999	43,131	Apr 25 09:38 PM
Facteau Bill	Director	Apr 23 '25	Buy	1.91	13,123	24,999	13,123	Apr 25 09:37 PM
Blank Andrew Scott	Director	Apr 23 '25	Buy	1.91	131,233	249,999	265,957	Apr 25 09:36 PM
STERTZER SIMON H	Director	Apr 23 '25	Buy	1.91	104,986	199,998	120,365	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 23 '25	Buy	1.91	26,246	49,999	138,966	Apr 25 09:35 PM
Altman Peter	President and CEO	Apr 15 '25	Buy	2.14	100	214	112,720	Apr 17 07:44 PM
Altman Peter	President and CEO	Apr 11 '25	Buy	2.03	300	609	112,620	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 10 '25	Buy	1.99	300	597	112,320	Apr 14 07:41 PM
Altman Peter	President and CEO	Apr 07 '25	Buy	1.96	500	980	112,020	Apr 08 05:01 PM
Altman Peter	President and CEO	Apr 04 '25	Buy	2.04	800	1,632	111,520	Apr 07 05:10 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.20	600	1,320	110,720	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 02 '25	Buy	2.23	500	1,115	110,120	Apr 04 05:04 PM
Altman Peter	President and CEO	Apr 03 '25	Buy	2.24	1,200	2,688	109,620	Apr 03 09:08 PM
STERTZER SIMON H	Director	Mar 05 '25	Buy	2.45	1,000	2,450	57,138	Mar 07 08:30 AM
STERTZER SIMON H	Director	Mar 03 '25	Buy	2.30	22,753	52,332	40,602	Mar 05 08:30 AM
STERTZER SIMON H	Director	Mar 04 '25	Buy	2.30	15,536	35,733	56,138	Mar 05 08:30 AM
Altman Peter	President and CEO	Mar 03 '25	Buy	2.11	500	1,055	108,420	Mar 04 08:30 AM
Altman Peter	President and CEO	Feb 07 '25	Buy	2.48	600	1,488	107,920	Feb 11 05:42 PM
Altman Peter	President and CEO	Jan 29 '25	Buy	2.40	500	1,200	107,081	Jan 30 08:36 PM
Altman Peter	President and CEO	Jan 30 '25	Buy	2.38	239	569	107,320	Jan 30 08:36 PM

COSM

CABA

ACRV

NEWT

AIRJ

YORW

DLPN

NEOG

BCDA

Upgrade your FINVIZ experience